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LITERATURE REVIEW 
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1. Introduction to Neonatal Immunity 
The transition of a newborn from a sterile intra-uterine environment to the microbe-rich 
world we live in marks a unique immunological milestone. At this moment, an infant 
encounters both microbial friends and foes which will shape the health of the newborn 
throughout infancy and, potentially, well into adulthood. During the first few moments of 
extra-uterine life, the newborn will come into contact with a host of microbes that will 
colonize the skin and mucosal surfaces to establish commensal communities that 
ultimately benefit a newborns health. At the same time, there is a heightened potential for 
pathogenic organisms to attack the infant host, especially given the immaturity of the 
immune system and lack of immunological memory. To better understand the neonatal 
immune system, it is necessary to consider the developmental events that shape this 
system before birth.  
During gestation, it is critical that the fetus develops in a sterile environment as 
intra-uterine infections and the associated inflammation have been linked to infant 
mortality or preterm birth-related morbidity including neural injury such as 
intraventricular hemorrhage, white matter damage, and cerebral palsy
1
, cardio-respiratory 
distress
2
, and renal failure among many others
3
. In the first trimester, infection-induced 
tumor necrosis factor (TNF) and interleukin-1 (IL-1) are associated with pre-mature 
labor and delivery
4
. Inflammatory responses are also linked to alloimmune reactions 
between the mother and fetus which may result in spontaneous abortion
5
. It is also 
believed that adaptive responses biased toward Th2 cells and away from Th1 ensures a 
successful pregnancy
6
.  
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To avoid these deleterious inflammatory responses, a physical barrier is required 
to protect the growing fetus -- namely, the placenta. While the placenta serves as an 
immunological barrier to maintain separation between the maternal and fetal immune 
systems and also providing barrier protection against invading microbes, it renders the 
infant immunologically naïve upon birth.  
The lack of immunological memory, in combination with the immaturity of 
immune cells and tissues, contribute to high global infant mortality rates. It is estimated 
that, globally, 2.8 million infants die each year during the neonatal stage (the first 28 days 
of life) and that nearly a quarter of these deaths are directly due to infection
7
. While 
public health initiatives across the world have tremendously improved mortality rates 
over the past 25 years (Fig 1.1), the rate of progress is far behind the under-five survival 
(Fig 1.2). In fact, a closer look at this data reveals that the number of neonatal deaths as a 
percentage of all deaths that occur in children under the age of 5 is actually increasing
8
. 
This highlights an important gap in our understanding and treatment of neonatal diseases 
and calls for a greater push for neonatal immunity research.   
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Figure 1.1. Estimated Global Neonatal Mortality Rates. Estimates developed by the 
UN Inter-agency Group for Child Mortality Estimation and represented here as # of 
deaths per 1000 live births. Adapted from
8
. 
 
Figure 1.2. Estimated Neonatal Deaths as Percentage of Under-Five Deaths. 
Estimates developed by the UN Inter-agency Group for Child Mortality Estimation. 
Adapted from
8
. 
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The scientific community’s interest in neonatal immunity was sparked by seminal 
work by Sir Peter Medawar during the 1950’s when he discovered that fetal exposure to 
antigen induces tolerance toward that antigen later in life
9
. It should be noted that this 
concept was predicted in 1949 by Australian scientist Frank Burnet
10
 and together Burnet 
and Medawar share a Nobel Prize. Fascinatingly, Medawar’s research began as an 
endeavor to solve the problems involved with skin graft rejections seen in injuries 
sustained by soldiers in WWII. He, along with his postdoctoral fellow, Billingham, and 
graduate student, Brent, found that when cells from one mouse strain were injected into a 
fetal mouse of a different mouse strain the recipient would later grow into an adult 
capable of accepting a skin graft from the donor strain. This is in contrast to the 
phenomenon of rejection that occurs when a mouse is not exposed in early life. This 
concept became widely accepted and the neonatal period was considered a developmental 
window in which induction of immunological tolerance can be achieved. One can 
imagine the theoretical usefulness of this situation where later life ailments such as 
transplant rejection, autoimmunity, and allergy could all be avoided by careful 
administration of the antigen in early life. However, practicality and our failure to predict 
which future antigens to target have thus far precluded these therapeutic approaches.     
As science progressed and neonatal immunity research blossomed in the 1990’s, it 
became clear that the neonatal period represented more than just a state of tolerance and 
immune responses could be mounted. This notion came after the discovery of distinct T 
helper subsets in 1986
11
 where evidence suggested that mice challenged with antigen 
during the neonatal period preferentially induce non-inflammatory T helper type 2 (Th2) 
responses later in life
12, 13, 14, 15, 16, 17
. Surprisingly, in certain situations, T helper type 1 
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(Th1) responses could also be induced
15
. Such was the case when oral neonatal antigen 
exposure to myelin basic protein was shown to exacerbate later experimental 
autoimmune encephalomyelitis (EAE) disease progression
18
. However, Habib 
Zaghouani’s lab demonstrated that a self-antigen immunoglobulin chimera given during 
the neonatal period was protective against the development of EAE
19
 which hints to the 
importance of antigen type and delivery in dictating immune outcomes, an idea that will 
be important in later sections of this document. What ultimately emerged from these 
neonatal studies is that Th2 responses, which are largely non-inflammatory, far outweigh 
the pro-inflammatory Th1 responses which bodes well with the protective effect of 
Medawar’s transplant experiment and also provides insight into why neonatal vaccines 
often fail to protect against later infections. 
If the scientific community is to address public health concerns involving 
neonatal morbidity and mortality it is critical to understand the unique immune 
environment of the neonate.  
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2. Immune Cell Development 
 
All blood cells, including those of both innate and adaptive immunity, erythrocytes, and 
megakaryocytes, arise during the process of hematopoiesis. While it is appreciated that 
hematopoiesis occurs in the adult bone marrow, special consideration is taken to 
understand this process during neonatal development as hematopoiesis begins in the early 
fetal yolk sac, proceeds transiently through the liver, and finally settles in the bone 
marrow by term gestation. In early embryogenesis, it is thought that endothelial and 
hematopoietic cells both stem from the same cluster of mesoderm which presents, by 
three weeks of gestation, as thick primordial blood islands where the expression of CD34 
is shared between both endothelial and hematopoietic cells in support of their common 
precursor
20, 21
. Both erythroid and granulo-poietic progenitors have been characterized in 
the yolk sac as early as 25 days of gestation, remain constant between day 35-50, and are 
completely gone by day 60
22, 23
. However, the presence of these early progenitors in the 
yolk sac don’t necessarily indicate functional differentiation, especially since the cells 
produced in the early yolk sac predominantly become primitive nucleated erythrocytes to 
synthesize embryonic hemoglobin
21
.  
The transition from yolk sac hematopoiesis to other fetal organs initiates with the 
onset of cardiac beating/blood circulation and coincides with the switch from primitive 
erythroid production to definitive non-nucleated erythrocyte production, a designation 
defined by the type of hemoglobin synthesized by each cell
24, 25
. Despite the stable 
production of primitive cells from the yolk sac between days 35-50, cardiac beating, and 
therefore fetal liver hematopoiesis, has been demonstrated to occur as early as three 
weeks of gestation although at very low frequency. The detection of rare CD34- 
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erythro/myeloid progenitors in the liver is thought to represent a first wave of hepatic 
colonization but that the more mature CD34+ progenitors enter during a second wave 
only after day 32
20, 21
. Recent discoveries have identified that well after cardiac 
circulation is established, around 7-8 weeks the major source of hematopoietic stem cells 
(HSCs) is derived from endothelial cells of the aorta
26, 27, 28
 and that this population will 
seed the liver, thymus, and spleen where hematopoiesis continues until 7 months of 
gestation
21, 29, 30
. Although hematopoiesis has been demonstrated in the bone marrow as 
early as 11 weeks
31
 the switch generally takes place at 7 months so that hematopoiesis 
occurs largely in the bone marrow by the time of birth.  
The process of hematopoiesis generates all blood cells from HSCs which undergo 
stepwise differentiation into distinct cell subsets. In the late 1980’s, Irving Weissman’s 
group first isolated and began characterizing HSCs
32, 33
. As HSCs are atop the 
hematopoietic hierarchy of development, they retain the unique ability to self-renew. In 
1994, Weissman’s group identified three distinct subsets of HSCs: Long-Term HSCs, 
Short-Term HSCs, and Multi-Potent Progenitors (MPPs)
34
. Only the MPPs, which lack 
self-renewal capacity but retain multi-lineage potential as their name implies, will 
continue on to become one of two oligopotent cells: common lymphoid progenitors 
(CLP) or common myeloid progenitors (CMP)
35
. CMPs can give rise to both 
megakaryocyte/erythrocyte progenitors (MEPs)
36
 and also granulocyte/macrophage 
progenitors (GMPs) which will eventually fill the entire innate immune branch
37
. CLPs, 
on the other hand, may become T cells, B cells, or innate lymphoid cells (ILCs)
38
. It 
should be noted that dendritic cells (DCs) represent a unique group in that they have been 
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shown to arise from both CMPs and CLPs
39, 40, 41
. The endeavor to understand the exact 
mechanism of commitment and differentiation of DCs is an ongoing process.  
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3. Innate Immunity in the Neonate 
 
Innate immunity serves as the initial shield in defense against microbes while also 
activating and mobilizing the adaptive immune system. Since neonates have a 
developmental delay in adaptive immunity, their innate immunity branch must be able to 
compensate to ensure protection. As mentioned in the introduction, the fetal and neonatal 
immune systems must face three major physiological challenges: protection from 
microbial infection at the maternal-fetal interface, avoidance of inflammatory Th1 
responses during gestation, and mediation of the transition to a microbe-filled extra-
uterine life
42
. As the majority of these demands require physical separation of the infant 
from either mom or pathogen, special consideration must be given to physiological 
barriers as they pertain to innate immunity in addition to specific innate cell types.  
 
Physiological Barriers of the Neonate 
Skin.  
As the human’s largest organ, the skin serves as a primary barrier to defend against 
invading pathogens. Epidermal development begins early in embryogenesis and matures 
with gestational age
43
. Before week 30 of gestation, the epidermis is weak and has a 
poorly formed stratum corneum (the outer most layer of skin) but by week 34 the 
epidermis is considered mature
44
. Interestingly, in this same study, Evans and Rutter 
show that the postnatal environment significantly contributes to epidermal development 
as prematurely born infants will have skin maturation that resembles term infants within 
two weeks of being born, regardless of gestational age. The evolutionary trait for infants 
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to quickly develop a healthy skin barrier highlights just how important this function is for 
human health.  
Another interesting feature of newborn skin is that it is much more alkaline than 
that of an adult. Whereas adult skin has pH of around 5.5
45
, newborn skin averages a pH 
of 7 on day 1 of life but already starts acidifying by day 2
46
. It is hypothesized that early 
life skin alkalinity may be due to the alkaline environment of amniotic fluid
43, 47
 and that 
skin acidification contributes to the maturation of barrier function
48
 by influencing the 
composition of microbial flora
49
. Skin acidification may also be influenced by the vernix 
caseosa, a waxy protective substance covering a newborns skin which is produced by 
fetal sebaceous glands during the last trimester of pregnancy. The vernix is composed 
mainly of water but contains proteins, lipids, and, importantly, antimicrobial peptides
50, 
51
.  
Antimicrobial peptides are perhaps one of the most important constituents of the 
newborn skin barrier. Skin from neonatal mice and humans express various antimicrobial 
peptides such as cathelicidin, -defensins, protegrins, bactericidal/permeability-
increasing protein, S100 proteins, lactoferrin, lysozyme, and RNAses
52, 53, 54
. While many 
skin and immune parameters are suboptimal in newborns, antimicrobial peptide levels are 
often increased during the perinatal period and may provide a compensatory mechanism 
for the developmental delay in other immune branches. In fact, gene expression levels of 
neonatal murine cathelicidin were 10- to 100-fold greater than in adult mice
52
. Similarly, 
protein levels of both lysozyme and lactoferrin were found to be greater in newborns 
immediately after delivery than in adults and these levels were not diminished after 
12 
 
 
 
bathing
55
 which represents some level of permanency and not just an effect of the uterine 
environment.  
Emerging from a relatively sterile intra-uterine environment to a world filled with 
microbes, it becomes necessary to allow rapid colonization of skin commensals while 
preventing colonization of pathogens. The newborn epidermis development, pH, and 
antimicrobial peptides mediate this transition to ensure health of the newborn.  
 
Intestine.  
Home to the vast majority of commensal bacteria, the intestines serve as a critical 
regulatory element for many aspects of human health such as immune system 
development, progression of multiple diseases, and, more recently appreciated, neural 
function. Newborns have traditionally been considered sterile at birth but this concept has 
recently been challenged by the detection of bacteria in meconium, the first stool to be 
passed after birth
56
. To support the idea that these bacteria were contracted in utero, 
Ardissone et al. showed that these bacterial populations are similar to those found in 
amniotic fluid
57
. Yet despite having the presence of some microorganisms, the overall 
microbial abundance and diversity of the newborn gut is low enough that the initial 
postnatal environment plays a pivotal role in defining and establishing the long-term 
microbial profile.    
Two major events largely shape the microbial communities during development. 
The first event is the initial microbial exposure of the infant. For many, this would be the 
vaginal flora during delivery whereas others born by cesarean would be exposed to 
external sources and these infants demonstrate delayed colonization. Furthermore, these 
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different exposures have been linked to disparate microbial profiles
58
. The second major 
colonization event occurs through the diet. Formula fed infants harbor Bifidobacteria, 
Bacteroides spp., and Clostridium spp. whereas babies fed breast milk have mostly 
Bifidobacteria
59
. Diet plays the most profound role later in infancy during the transition 
from milk to solid food and, surprisingly, the emerging microbial composition remains 
fairly stable throughout life
60, 61
. 
 Aside from harboring commensal microorganisms, the gut must be equipped to 
defend against pathogens and this function is largely tied to its physiological structure. 
There are considerable differences between mice and humans when assessing neonatal 
intestinal development. In general, humans are born with a much more mature gut than 
mice. The intestinal surface is characterized by a monolayer of polarized epithelial cells 
that comprise the only boundary between the “external” microbial content and “internal” 
host lumen
62
. Intestinal crypts are gland-like invaginations of the monolayer where 
various specialized cells reside deep within the crypt including mucus secreting goblet 
cells and anti-microbial secreting Paneth cells. In mice, crypts are not present until 12-15 
days after birth during the weaning period
63
 whereas humans display fully developed 
crypts by 19 weeks of gestation. Despite having complete gut architecture, human 
newborns still have a relatively “immature” gut since antigenic stimulation by the 
microbiota is required for full maturation
62
.  
 The gut barrier provides protection from pathogens by secreting mucus, defensins, 
and cathelicidins. The first line of defense is the mucus layer that provides physical 
separation of microbes and gut epithelium and is composed of mucin, the main structural 
component, and trefoil factors which aid in mucin polymerization--both of which are 
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produced by goblet cells
64
. In humans, mucin mRNA is detected quite early at 12 weeks 
of gestation
65
 and even preterm infants show rapid mucin production
66
. This early 
protective mucus layer is likely to be related to gut maturity as neonatal mice which have 
a relatively immature gut show delayed production of mucin as goblet cells are not yet 
present
62
. A study that assessed antimicrobial peptides in human meconium found high 
levels of -defensins HNP-1-2 and HD5 and the cathelicidin LL-37 which, since present 
at birth, may represent a defense system already in place to help control the establishment 
of gut microbiota and provide early life pathogen protection
67
. Similarly, Mathias 
Hornef’s group found that in very young mice there is an abundance of cathelicidins, 
particularly CRAMP, produced by epithelial cells to provide enteric protection in the 
early postnatal period and that cathelicidin production switches over to Paneth cells after 
crypt formation
68
. Overall, this high and stable production of mucus, defensins, and 
cathelicidins in humans provides early life protection against pathogens. Importantly, 
special consideration must be taken when making comparisons between mice and human 
newborn intestinal studies.  
 
Lung. 
The lungs are one of the last critical organs to form during development and therefore the 
majority of premature infants have some problems associated with respiration. In fact, 
lung alveolarization occurs between 36 weeks of gestation and continues throughout the 
first 36 months of life
69
. Since lung development is delayed it is no surprise that lung 
barrier function, largely provided by pulmonary surfactant, is also compromised in early 
life. Surfactant is comprised of 70-80% phospholipids, 10% protein, and about 10% 
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neutral lipids like cholesterol
70, 71
 and, along with barrier function, is critical for lung 
function as it reduces surface tension at the air/liquid interface preventing alveolar 
collapse
70
. Newborns have lower levels of surfactant than adults, especially prematurely 
born infants who display respiratory distress syndrome, the prototypical disease of 
surfactant deficiency. This surfactant deficit in early life renders newborns susceptible to 
pulmonary infection.  
 
Neonatal Innate Leukocytes 
The innate immune cells include neutrophils, monocytes/macrophages, dendritic cells 
(DCs), natural killer cells (NKs), and other granulocytes such as basophils, eosinophils, 
and mast cells. A hallmark of innate cells is the way in which they sense foreign antigens. 
Each cell expresses a set receptors that detect pathogen associated molecular patterns 
(PAMPs) which are molecules on pathogens that are not expressed by host cells. Such 
receptors include toll-like receptors (TLRs) and other pattern recognition receptors 
(PRRs). The history of TLR discovery is rich in Nobel awards. Toll receptors were 
originally identified in 1985 in Drosophila as a determinant in dorsal-ventral polarity 
during embryogenesis
72
 and later appreciated to activate immune functions
73, 74
. In 1997, 
Charles Janeway’s group, with the then-postdoc Ruslan Medzhitov as first author, 
identified the first human TLR and the associated downstream NF-B mediated 
production of inflammatory cytokines as well as the ability of TLR signaling to 
upregulate co-stimulatory molecule B7.1
75. A year later, Beutler’s group identified 
bacterial lipopolysaccharide (LPS) as the ligand for TLR4
76
. After this, a cascade of 
discoveries eventually identified TLR1-TLR13, although only TLR1-10 are found in 
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humans where TLR1, 2, 4, 5, and 6 are found on the cell surface and function to 
recognize microbial membrane components and TLR3, 7, 8, and 9 are found in 
intracellular compartments and recognize intracellular microbial nucleic acids
77
. 
Regarding neonates, the expression levels of TLRs and their accessory and adaptor 
proteins are developmentally linked with gestational age so that pre-maturely born infants 
express lower levels than term infants
78
 but a term infant will express levels consistent 
with adults, albeit with reduced functional capacity
79
. Specific functions of different 
innate cells of the newborn will be discussed below. 
 
Neutrophils. 
As the innate immune system is the main defense against newborn infections, neutrophils 
play a critical role as they are the first circulating cell type to respond to infection.  
However, neonates begin their lives at a disadvantage due to their low frequency of 
neutrophils. Neutrophils exist in three different pools: proliferative, circulating, and 
marginating
30
. The proliferative pool resides in the bone marrow and comprises 
precursors that have the ability to multiply and restore peripheral neutrophil numbers. In 
the neonate, the proliferative pool is just 10% of that in an adult
80
. During an infection, 
the proliferative pool of neutrophils is called to migrate to the periphery to aid in 
pathogen clearance and, because neonates have a limited number of these cells to begin 
with, they often develop neutropenia. This is particularly the case in neonatal sepsis 
where both cell number and the kinetics of the neutrophil response are compromised in 
newborns
81
. In an animal model, the neutrophil responses take 3-4 hours to initiate in a 
neonate whereas an adult can mount a response in about an hour
82
. Pre-maturely born 
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infants seem to be the most disadvantaged in this aspect as the proliferative capacity of 
progenitor cells increases rapidly with age until adult-like cell frequencies occur 4 weeks 
after birth
83
.  
 The functional capacity of neutrophils relies on their ability to recognize PAMPs, 
utilize chemotaxis to migrate to sites of infection, extravasation into the tissue, and 
perform effector functions such as phagocytosis, degranulation, and release neutrophil 
extracellular traps (NETs). Neonatal neutrophils display some reduced function when 
compared to those from adults. While neonates and adults express similar levels of most 
TLRs, TLR4 expression is greatly reduced in the newborn and contributes to their 
inability to mount strong responses against LPS-harboring pathogens as evident by 
limited production of IL-1, IL-6, and TNF-78. Even though the other TLRs are 
expressed at adult levels, PAMP signaling elicits reduced inflammatory cytokine 
responses during the neonatal period, indicating functional developmental deficits. 
Regarding chemotaxis, neonatal neutrophils display impairment compared to those from 
adults but this reduced ability subsides by 4 weeks of age. Specifically, both neonatal and 
adult neutrophils responded to 7 known chemotactic agents in the same relative order of 
potency (i.e. IL-8 was the strongest but GRO- was the weakest) but the neonatal 
neutrophils migrated significantly less distance
84
. The cause of reduced mobility is 
thought not to rely in the abundance or affinity of surface receptors, as they are expressed 
similar to adult, but instead signaling abnormalities stemming from low intracellular 
calcium mobilization
85
. Once at the site of infection, neutrophils from neonates will 
encounter a greater challenge in extravasation as they display reduced expression and 
shedding of L-selectin
86
 and diminished upregulation of CR3
87
. 
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An important function of neutrophils is their ability to phagocytose microbial 
agents. Both neonatal and adult neutrophils are able to phagocytose both Gram-negative 
and Gram-positive bacteria at similar levels with a deficit only witnessed in preterm 
infants
88
. Neutrophils must also degranulate and release microbicidal agents. While adult
and neonatal neutrophils display similar abilities to release bactericidal/permeability-
increasing protein (BPI), lactoferrin, and elastase, prematurely born infants display 
significant impairment
89, 90
. Additionally, the concentration of lactoferrin within neonatal
neutrophils is half of that measured in adult neutrophils
91
. Finally, the ability of neonatal
neutrophils to produce NETs relies exclusively on the ROS-independent pathway in 
which exposure to pathogens activates complement, TLR2, or fibronectin
92, 93
 as they are
completely defective in NET production through the traditional pathway which requires 
activation of NADPH oxidase and ROS production
30
. Overall, neonates display some
levels of impairment in neutrophil responses but these are all corrected relatively quickly 
after birth so that by one month of age adult-like responses can be mounted. Neutrophil 
impairment becomes a much larger problem in prematurely born infants as they lack the 
very first line of defense and display much higher rates of infection such as early onset 
sepsis and necrotizing enterocolitis. 
Monocyte/Macrophage. 
Monocytes are a circulating leukocyte that can differentiate into either macrophages or 
myeloid DCs. Monocytes can be classified as classical (CD14+ CD16-), inflammatory 
(CD14+ CD16+) or patrolling (CD14
int
 CD16+). While the literature agrees that
frequencies of adult and neonatal classical monocytes are equivalent and express similar 
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expression of CD11c, CD80/CD86, CD163, and HLA-DR
94
, some evidence suggests
inflammatory monocytes are reduced in the neonate
95
 or that neonatal patrolling
monocytes are reduced
96
.  Furthermore, monocyte function has been shown to be
relatively equivalent to that of adults. Placental monocytes cultured in vitro secreted 
lysozyme, lost peroxidase activity, and displayed 5’-nucleotidase activity at similar levels 
as monocytes from adult blood
97
. The same study showed that both neonatal and adult
monocytes were subject to similar infection and intracellular replication of Toxoplasma 
gondii and that either cell type could prohibit replication if pre-treated with supernatants 
from lymphocytes primed with T. gondii, indicating complete functional maturity of 
neonatal monocytes. Other experiments have shown that cord blood monocytes display 
adult-levels of adherence, chemotaxis, bactericidal activity, phagocytosis-associated 
chemiluminescence, production of superoxide, and generation of hydrogen peroxide 
98
.
Moreover, in response to peptidoglycan (PGN), neonatal monocytes produce even higher 
levels of IL-12p70 and TNF than adult monocytes
94
. Together, any immune deficits of
the neonate are not likely to be contributed to the monocyte compartment. 
Despite healthy monocytes in neonates, there does appear to be a deficiency in 
neonatal macrophage responses, particularly toward polysaccharide antigens. When 
stimulated with LPS, neonates failed to produce IL-1, IL-12, and TNF but instead made 
more IL-6 and IL-10 than adult counterparts
99
. However, as previously described,
neonates do not display high levels of TLR4 which could contribute to the suppressed 
LPS response. 
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DCs. 
Dendritic cells may be the crux of neonatal immunity as they are critical in initiating an 
adaptive response yet show profound developmental delays.  First described and named 
in 1973 by Ralph Steinman
100
, dendritic cells function to take up, process, and present
antigen to lymphocytes as well as produce cytokines which aid in this process. Most of 
the knowledge on dendritic cell development comes from murine studies so for this 
section, unless specifically stated otherwise, the information presented will be relevant to 
mice. In the murine neonate, dendritic cells first appear in the thymus by day 17 of 
embryonic development when thymocyte selection begins
101
. At birth, splenic DC
frequency is extremely low, comprising just 0.2% of the total splenic cells and does not 
reach adult levels until 6 weeks of age. Interestingly, plasmacytoid dendritic cells (pDCs) 
represent a larger frequency (45%) of the DC population at one week of birth which 
eventually decreases to 20% by week 6 as the other DC populations expand
101, 102
. pDCs,
which express CD11c
lo
 produce large amounts of IFN in a short period of time, are
considered the first line of defense against viral infections whereas conventional DCs 
(cDCs), which express CD11c
HI
 contribute to T cell induction and are critical in
mounting a strong adaptive response
103
.
Dendritic cells can be categorized based on the expression of surface markers 
such as CD11c, CD8, CD4, CD103, CD11b, and others as listed in Figure 1.3. Regarding 
cDCs found in lymphoid organs, the CD11c
+
 CD8
-
 subset is the first to emerge in the
neonate followed by the CD11c
+
 CD8
+
 subset by day 6 or 7
101, 104, 105
. The delayed
emergence of the CD8
+
 subset has a major functional consequence as these cells
contribute to the generation of Th1 responses through IL-12 production
104
. IL-12p70,
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comprised of IL-12p40 and IL-12p35 subunits, is one of the cytokines that, 
developmentally, takes the longest to reach adult levels upon TLR stimulation
106
. This is
thought to be due to defective transcription of the IL-12p35 subunit in neonates
107
.
Plasmacytoid DCs, on the other hand, show relatively little functional defect compared to 
adult pDCs
101, 108
.
Human neonate DC studies rely on cord blood cells and cDCs present in the blood 
are considered to be immature cells that are transitioning from the bone marrow to 
peripheral tissue. The ratio of pDC:cDC of human cord blood is essentially reversed (3:1) 
to that found in adult blood (1:3)
109
 and exist in a more immature state as evident by
decreased expression of HLA-DR, CD80, CD86, and ICAM-1
103, 110, 111
. Together, 
neonatal DCs show both developmental delays and functional defects, especially 
regarding their ability to produce IL-12 and generate a productive pro-inflammatory Th1-
type response. 
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Figure 1.3. Murine and Human Dendritic Cell Populations. Comparison of different 
murine and human dendritic cell subpopulations based on cell surface markers. Source: 
https://www.biolegend.com/dendritic_cells. 
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Innate lymphoid cells. 
The recently classified innate lymphoid cells (ILCs) comprise three subsets: ILC1 
(includes NK cells), ILC2, and ILC3 (includes lymphoid tissue inducer cells, LTi). They 
mirror T helper cells in their transcriptional profile and cytokine production but differ in 
that they do not express a T cell receptor (TCR). ILC1s include NK cells, express T-bet 
transcription factor, and functionally parallel Th1 cells through production of IFN and 
TNF. ILC2s are similar to Th2 cells by way of Gata3 dependence and IL-13, IL-5, and 
IL-9 secretion. ILC3s are counterpart to Th17 cells, require RORt, and make IL-17 and 
IL-22. Since these cells do not express specific antigen receptors, they are considered 
innate as the only stimulus required for cytokine production is receipt of the respective T 
helper cell polarizing cytokine. For example, IL-12 or IL-18 will cause an ILC1 to 
produce IFN or TNF whereas IL-25, IL-33, or TSLP will induce IL-13 or IL-5 secretion 
by ILC2s. With the exception of NK cells, ILCs have only been described in the last 10 
years and relatively little is known on their function in neonatal immunity. 
Neonates display higher numbers and percentages of NK cells in blood than 
adults
112
 despite their lowered NK cell cytotoxicity and antibody-dependent cellular
cytotoxicity
113, 114
. However, enhanced cytotoxicity may be rapidly acquired by IL-15
which is produced by neonatal macrophages and monocytes
115
 which would suggest that
neonatal NK cells are poised to quickly respond to viral infection if stimulated in the 
correct context. 
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Basophils/Mast cells/Eosinophils. 
The hallmark cells of allergic responses, basophils, eosinophils, and mast cells are low 
frequency granulocytes that release immunomodulatory and often highly inflammatory 
granules, such as histamine, heparin, and leukotrienes, upon stimulation. Paul Ehrlich 
characterized each of these cells in the late 19
th
 century early in his career with the
discovery of mast cells included in his doctoral thesis work
116
. While basophils represent
just about 1% of circulating blood cells, they are potent effectors of IgE-mediated 
immune responses. When multivalent antigens are recognized and bound by IgE, the Fc 
portion of IgE binds to the α chain of its high-affinity receptor, FcεR1, on the surface of 
basophils and mast cells. Aggregation of the receptor complex leads to Lyn 
phosphorylation of the β and γ subunits of FcεR1 which recruits Syk kinase and 
ultimately leads to cell activation and degranulation
117, 118
. However, it is now 
appreciated that basophils function beyond IgE-mediated responses and produce 
appreciable quantities of both IL-4 and IL-13 cytokine
119, 120
. Interestingly, there is also
evidence that these cytokines influence basophil differentiation and function. Mice that 
lack the type II IL-4 receptor, through which both IL-4 and IL-13 can signal, have 
reduced frequency of basophils and basophil progenitors and their basophils were less 
likely to produce IL-4 upon TLR stimulation than wild type counterparts
119
. In the
neonate, basophils are present and produce enough IL-4 to skew adaptive immune 
responses toward Th2 cells by signaling through the HR on DCs to dampen their IL-12 
production. The reduced levels of IL-12 is enough to polarize naïve T cells toward Th1 
but not enough to counter IL-13Ra1 upregulation on the Th1 cell which later serves as a 
death marker. 
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Mast cells are similar to basophils except they do not circulate and are instead 
tissue-resident, often found in blood vessels and epithelial surfaces
121
. Mast cells can be
activated through IgE binding FcεR1, as with basophils, or through complement 
components C3a and C5a, and TLR ligands. Mast cells are found in neonates and can 
even be isolated from the umbilical cord. Surprisingly, both neonatal mast cells and 
basophils produce significantly more histamine than adult counterparts
122
 which may
contribute to the prevalence of allergic responses in newborns. Prematurely born infants 
are prone to develop chronic lung disease of prematurity which is characterized by 
impaired alveolarization, lung scarring, and inflammation which are concurrent with, and 
likely due to, mast cell hyperplasia
123
.
Eosinophils comprise ~1-5% of peripheral blood and while they serve important 
anti-helminth roles, they are highly involved in allergy associated inflammation such as 
asthma and eosinophilic oesophagitis
124
. As neonates have increased type II cytokines
and these cytokines are perpetuated by eosinophils, it is not surprising that newborns 
suffer from eosinophilic diseases. Up to 76% of prematurely born babies are reported to 
develop eosinophilia
125
 which has been linked to the development of atopic diseases
within the first 18 months of life
126, 127
. Overall, neonates have no defect in granulocytes
such as basophils, mast cells, or eosinophils which may contribute to adverse responses 
in the developed world. 
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4. Adaptive Immunity in the Neonate
The adaptive immune branch serves to provide specific and long lived protection against 
pathogens and serves an important role in vaccine responses. Unfortunately, this branch 
is compromised in neonates and doesn’t fully mature to provide adult-like protection until 
later in life. The adaptive immune system is comprised of T lymphocytes and B 
lymphocytes which develop in the thymus and bone marrow, respectively. T cells 
mediate cellular immune responses by producing cytokines to enable phagocyte 
activation as well as performing cytotoxic functions to eliminate pathogen infected cells 
whereas B cells contribute to humoral immunity by generating antibodies which bind 
specific pathogens to neutralize and target them for destruction. 
T Lymphocytes 
T lymphocytes originate from precursor cells in the bone marrow which home to the 
thymus where they complete their development. During their stay in the thymus, T cells 
acquire their unique and vastly diverse T cell receptor through V(D)J recombination and 
positive and negative selection. These processes, while outside of the scope of this 
literature review, ensure that foreign antigen can be recognized by at least one of the T 
cells and that none of the T cells respond to self-antigens. In the human neonate, T cells 
arise fairly early in gestation and by delivery at term the frequency of T cells (19-26% of 
blood leukocytes) is similar to that of adults (24-30%) and the CD4:CD8 ratio of both 
newborns and adults is between 1.2:1 and 2:1
128
. However, a study investigating
prematurely born human infants found that the number of CD4 and CD8 T cells were 
markedly lower than in term infants
129
 indicating that there is a developmental delay in T
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cell emergence but that this defect is corrected by the time birth occurs at full term. In 
mice, however, T cell generation is delayed. In fact, the αβ TCR isn’t detectable until day 
16-17
130
 of the murine 20-day gestation with appreciable numbers of functional T cells
emerging in the thymus around day 19
131
. For this reason young mice do not reach adult
percentages of lymphocytes in the spleen until day 15 after birth and in the lymph nodes 
until 7 days of life
132
. The emergence of T cells from the thymus leads to lymphopenia-
induced proliferation of naïve neonatal thymocytes which generates a peripheral T cell 
population that is CD44
bright
 and thus considered memory-like
133
 which perhaps
contributes to the differences in T cell function between adult and neonatal mice. 
There are various subsets of CD4
+
 T helper cells: Th1, Th2, Th17, Tfh, and Tregs
are the major types and are classified based on the cytokines they produce. With the 
exception of natural Tregs (nTregs), which are generated though strong TCR stimulation 
during thymic selection, each T helper subset is generated from naïve CD4 T cells in the 
periphery and their decision to polarize toward a specific subset depends on the 
surrounding cytokine milieu as dictated by the context of infection. Neonatal T cells 
preferentially polarize toward Tregs and Th2 which shift them away from the more pro-
inflammatory Th1, Th17, and Tfh subsets
134
 (Figure 1.4).
 Evidence for the propensity of naïve neonatal T cells to polarize toward T 
regulatory cells instead of other cell types demonstrates that up to 70% of neonatal 
CD4
+
Foxp3
- 
thymocytes become Foxp3
+
 cells upon TCR stimulation as opposed to only
0.2% of adult thymocytes
135
. Further investigation in the same study showed that TCR
and costimulation were sufficient to drive neonatal Treg polarization even in the absence 
of exogenous TGF-β and IL-2 and that this capacity is a developmental trait that 
28 
 
 
 
disappears with age. It is interesting to note, however, that Foxp3-expressing nTregs are 
absent in the murine neonate until about day 4 of life and slowly increase in frequency to 
adult levels by day 21
136
.  
As with Tregs, neonatal naïve CD4 T cells also prefer to become Th2 cells. 
Unlike adult cells which require polarization and several rounds of cell division, freshly 
isolated murine CD4
+
 lymph node cells rapidly produce the Th2 cytokines IL-4 and IL-
13 within 24 hours of stimulation
137
. This rapid effector-like function is possible because 
the regulatory element, CNS-1, within the Th2 locus in T-lineage cells exists in a 
hypomethylated state, which enhances transcription, in neonates whereas adult CNS-1 is 
hypermethylated and thus transcription is repressed. The same group later defined the 
developmental window of CNS-1 hypomethylation as beginning in mid-gestation and 
continuing throughout the first week of life
138
. This phenomenon has also been 
documented in human cord blood CD4 T cells where the chromatin in the IL-13 locus is 
maintained in an accessible configuration as determined by DNase I hypersensitivity and 
hypomethylation
139
. Interestingly, the human IFN-γ locus in cord blood CD4 T cells is 
hypermethylated
140
, indicating an intrinsic repression of Th1 cytokine responses in early 
life. While this neonatal Th2 bias is thought to serve an important role in maintaining 
pregnancy
6
, the absence of Th1, Th17, or Tfh cells impairs the protection of the neonate 
against pathogens.  
It has long been reported that neonates have defective Th1 responses which 
explains the window of tolerance originally observed by Medawar and the susceptibility 
of neonates to infection. Even though this defect plays a critical role in the maintenance 
of pregnancy, it would benefit the newborn to be able to quickly adapt to extra-uterine 
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life and switch on the ability to generate Th1 cells. Decades of research have elucidated 
mechanisms in which the neonatal system can be manipulated in order to generate 
effective Th1 immunity. For example, injection of IL-12 can prevent Th2-dominant 
responses and reverse transplantation tolerance in neonatal mice
141
 which agrees with 
studies highlighting the importance of robust DC function in initiating Th1 responses
104
. 
Certain early life viral infections, such as Cas-Br-E murine leukemia virus
142
 or a 
vaccinia-based viral vector
143
, have also shown to induce protective Th1 responses upon 
later infection. Even though the default pathway for neonatal T helper polarization is 
toward Tregs and Th2 cells, it is possible to generate protective Th1 immunity given the 
appropriate context.  
Until recently, functional studies involving murine neonates were restricted to 
analysis of the secondary response and, while this yields important information regarding 
how neonatal exposure affects health later in life, it doesn’t really address how the 
immune system operates at the neonatal stage and how newborns can combat early life 
infection. The absence of primary response analyses stems from technical limitations 
associated with studying newborn mice and only modern laboratory techniques have 
afforded the ability to perform assessment of primary responses. These studies utilized a 
neonate-to-neonate adoptive transfer model and demonstrate that neonates do have the 
ability to mount balanced Th1/Th2 primary responses but that during a subsequent 
antigen challenge the Th1 cells die which leads to biased Th2 immunity
144
. Interestingly, 
they found that the death of Th1 cells is due to expression of IL-13Rα1, which forms a 
cytokine receptor complex with IL-4Rα through which both IL-4 and IL-13 can signal, 
on Th1 cells and that during the recall response, neighboring Th2 cells produce IL-4 and 
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IL-13 which induces apoptosis upon binding to their receptor on Th1 cells. Furthermore, 
the expression of IL-13Rα1 on Th1 cells is a developmentally controlled trait which 
manifests from birth through around day 6 of murine life
104
. Studies that investigate the 
apoptotic pathway induced by IL-4 and IL-13 in Th1 cells may provide avenues in which 
preservation of Th1 cells is possible.   
Much less is known on the development of neonatal Th17 cells. It is likely that 
differentiation is shunted away from the Th17 pathway and toward the Treg pathway due 
to the absence of pro-inflammatory cytokines. In the presence of TGF-β during T cell 
activation, a cell upregulates both Foxp3, the master transcriptional regulator for Tregs, 
and RORγt, the regulator for Th17 cells, but when cytokines like IL-6, IL-1β, and IL-23 
are absent, Foxp3 is able to preside and the cell will become a Treg instead of a Th17
134
. 
Furthermore, the dominant Th2 pathway may also prevent Th17 differentiation as 
blockade of IL-4 during allogeneic cell transfer prevents tolerance and allows for the 
development of alloreactive Th17 cells
145
.  That said, certain adjuvants and infections are 
capable of stimulating a Th17 response in neonates such as the IC31 adjuvant
146
 or 
infection with Yersinia enterocolitica
147
 which, like Th1 cells, indicates that the correct 
stimulation conditions can induce protective immunity.  
T follicular helper (Tfh) cells are critical for the generation of productive B cell 
responses and subsequent antibody production. Similar to Th1 and Th17 cells, it appears 
as though neonates have reduced capacity to generate Tfh cells but that they can be 
induced under certain circumstances. For example, IL-4 negatively regulates the 
generation of Tfh cells
148
 which explains the relative paucity in neonates but adjuvants 
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with CpG oligonucleotides can overcome this defect and allow for robust germinal center 
responses and provide protective B cell responses
149
.  
 Like CD4
+ 
T helper cells, CD8
+
 cytotoxic T cells are also thought to be less 
effective in the neonate. A recent study investigating the transcriptional profile of human 
neonatal CD8 T cells found that they are transcriptionally distinct from their adult 
counterparts in that they have reduced expression of TCR and cytotoxicity related genes 
but upregulated genes involved in antimicrobial peptide generation and production of 
reactive oxygen species which led the authors to conclude neonatal CD8 T cells are 
innate-like
150
. As with other cell types, specific circumstances license full adult-level cell 
activity. Congenital infection with Trypanasoma cruzi leads to a high frequency of 
pathogen-specific CD8 T cells in cord blood indicating a very early life ability to 
generate CD8 immunity
151
. Furthermore, in a murine model, adult level CD8 T cell 
responses can be induced in neonates using plasmid DNA vaccines
152
.  Circumstances 
that induce protective CD8 T cell responses often correlate with protective Th1 immunity 
as well.  
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Figure 1.4. Neonatal CD4 T cell polarization. The relative propensity of neonatal naïve 
T cells to polarize toward a specific subset is indicated by the thickness of the arrow and 
is guided by the listed cytokines. Adapted from Debock et al, 2014.
134
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B Lymphocytes 
B cells are tasked with the important duty of generating pathogen specific antibodies to 
quell current and future infections. B cells arise in the bone marrow where they undergo 
V(D)J recombination to express a unique IgM B cell receptor. These cells are then 
released into the circulation as immature IgM
+
IgD
-
 cells which finish their maturation 
into IgM
lo
IgD
hi
 mature B cells. Mature B cells circulate throughout lymphoid organs and 
migrate into the B cell follicle where the T-B interactions can occur, B cell differentiation 
takes place, and germinal centers are formed which support somatic hypermutation and 
isotype class switching eventually producing memory B cells and antibody-generating 
plasma cells. This process varies in mice, especially in regards to early life B cell 
development. For example, in mice, B cells are produced in the fetal liver and spleen 
until well into the first week of life when production switches to the bone marrow
153
. 
Additionally, B cell follicles are not found in mice until 7-10 days after birth and 
germinal centers do not form until 3 weeks. For these reasons, productive humoral 
immunity is difficult to induce in early life.  
 It is also important to consider the difference between B cell subsets. B-1 cells are 
produced first in early life, largely reside in pleural/peritoneal cavities, do not self-renew, 
and do not require T-cell help as they do not undergo somatic hypermutation or develop 
memory. B-2 cells, however, are the typical marginal zone or follicular B cell that arises 
after birth, resides in secondary lymphoid organs, and requires T-cell help for somatic 
hypermutation and memory development. B-2 cells are the major players in vaccine 
responses and their absence in early life may help explain poor neonatal vaccination. 
Indeed, neonatal responses to vaccination are characterized by lower affinity and reduced 
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heterogeneity of IgG with a delayed onset and shorter duration of antibody production
154
. 
This defect is age-dependent as the earlier an infant is immunized the worse their 
responses will be, regardless of maternal antibody
155
. For this reason, the ideal vaccine 
schedule in young children consists of repeated injections of the vaccine to boost the 
response and perpetuate memory cells.  
 Some factors extrinsic to B cells also contribute to neonatal humoral immunity 
such as the presence of maternal antibody which can circumvent neonatal B cell 
responses. IgG antibodies that a fetus acquires through trans-placental maternal transfer 
are able to bind pathogens and direct them for destruction by innate cells. This is 
especially effective in protection from respiratory syncytial virus
156
 and influenza
157
. This 
process is so effective, lasting for 6 months, that pregnant mothers may receive booster 
shots in order to provide protection for their infants as is common with the Tdap vaccine 
to protects against tetanus, diphtheria, and pertussis. Despite the protection afforded by 
maternal antibody, there are negative consequences when considering the efficacy of 
neonatal vaccination as maternal antibodies may bind to vaccine antigens and mask their 
ability to generate protective immunity in newborns. This topic will be explored in 
greater detail in the following section. 
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5. Neonatal Vaccinations 
It should be apparent by now that neonates have broad impairments in their immune 
function but that certain circumstances are able to evoke strong responses. The case is no 
different in the context of neonatal vaccinations. In general, vaccine responses are quite 
poor in early life and are characterized by failure to mount antigen specific memory to 
most antigens. This defect is age-related and a gradual increase in function occurs 
throughout postnatal development. However, it is possible in some situations to 
overcome the challenges associated with neonatal vaccinations and elicit protective 
immunity.  
 The cause for poor vaccine responses stems from both cellular immaturity, as 
discussed in detail in the preceding sections, and from physiological immaturity along 
with the presence of maternal antibody. Physiological immaturity is characterized by 
poor secondary lymphoid organ architecture that fails to generate B cell-mediated 
adaptive immune responses. The splenic marginal zone (MZ) is poorly developed at birth 
and does not fully form until 2-3 weeks in murine neonates and 1-2 years in humans
158, 
159
. Interestingly, a study that investigated post-mortem human spleens from very young 
infants/children found that the MZ was often completely missing in babies that 
succumbed to sudden infant death syndrome and/or infection
160
. Furthermore, neonates 
display reduced germinal centers (GC)/germinal center reactions in both mice
153
 and 
humans
161
 which is thought to be due to immature follicular dendritic cells which fail to 
attract B cells and nucleate the GC reaction
154
.  
The contribution of maternal antibody also undermines vaccine efficacy in early 
life. It is thought that maternal antibody present in the neonate may directly bind vaccine 
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antigens and mask them from neonatal immune recognition or through IgG binding to the 
FcγRIIB162. The latter type of suppression occurs when a maternal IgG binds to FcγRIIB 
on antigen-specific neonatal B cells crosslinks with an antigen-loaded BCR on neonatal B 
cells
163. When this occurs, the tyrosine based inhibitory motif of FcγRIIB impedes the 
tyrosine based activation of the BCR and renders the B cell unresponsive. Maternal 
antibody has been shown to inhibit responses from all vaccine types: live-attenuated, 
inactivated, subunit, and experimental vaccines
162
. Strategies to overcome maternal 
antibody hindrance of early life vaccination may include increasing dose of antigen and 
discerning the earliest effective time point at which protection is afforded.  
Despite the disadvantage of the neonate to mount effective humoral immunity, 
there are, surprisingly, vaccines that work well in newborns. The Bacillus Calmette-
Guerin (BCG) vaccine which protects against childhood tuberculous meningitis and 
miliary disease is a live attenuated Mycobacterium bovis vaccine and is routinely given to 
infants at birth. It is the most widely used vaccine in the world, yet is not generally used 
in the US which has relatively low rate of tuberculosis
164
. The success of BCG is 
attributed to its ability to induce a Th1 response
165
 which may be due to robust activation 
of DCs. Even more exciting is that when BCG is given alongside other vaccines, like 
Hepatitis B, it increases the efficacy of the partner vaccine, yet this does not hold true for 
all partner vaccines since there was no synergy seen when partnered with vaccines for 
tetanus and diphtheria
166
. While it is not completely understood what makes BCG work 
so well in infants, it is clear that induction of protective immunity is possible in early life. 
Another effective vaccine given in infancy is for hepatitis B virus (HBV). The first dose 
of HBV vaccine is given at birth and followed by two boosters within the first six months 
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of life. As with many vaccines, boosters are often required, especially in early life to 
maintain protective titers. Such is the case with diphtheria-tetanus-acellular pertusis 
which is given at 2, 4, 6, and 15–18 months and Hib given at 2, 4, 6, and 12–15 months. 
For other vaccines, it is impossible to generate protective titers early in life and must be 
delayed until later, such as influenza which isn’t given until 6 months of age or MMR 
and Varicella which are delayed until 12 months
167
 
Since certain vaccines do elicit protective immunity at birth, it remains high 
priority to determine the mechanism of action and to replicate it in other vaccines. 
Promising results have been obtained when using vaccines that focus on intracellular 
antigen delivery such as the case with a single cycle HSV-1
168
 or an attenuated strain of 
Listeria monocytogenes which is an intracellular pathogen
169
. Along these same lines, 
DNA vaccines also allow neonates to mount protective immunity. In this case, the 
vaccine consists of a DNA vector that encodes antigenic portions of pathogens so that the 
antigens are generated by the host and processed intracellularly. When neonatal mice 
were vaccinated with a DNA vaccine against LCMV they demonstrated long-lived 
protection that was mediated by both CD8
+
 T cells and IgG1 and IgG2a producing B 
cells
170
. Furthermore, DNA vaccination is effective even in the presence of maternal 
antibody
171
. Approaches that include intracellular antigen delivery as well as potent 
adjuvants that aid in DC function may be the future key to establishing effective neonatal 
vaccinations.  
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CHAPTER II 
IL-4/IL-13 SIGNALING IN NEONATAL TH1 CELLS 
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1. Abstract 
It has long been observed that neonates have a bias toward Th2 immune responses, which 
explains the prevalence of allergic reactions, and relatively weak Th1 responses, allowing 
heightened susceptibility to microbial infection. Previous observations in a murine 
neonate-to-neonate transfer system indicate that, while Th1 cells actually arise alongside 
Th2 cells in the primary response, they undergo cytokine-mediated apoptosis during re-
challenge, resulting in the Th2 bias. Oddly, there is a developmental window in neonates 
where their Th1 cells express the IL-4/IL-13 heteroreceptor (HR) and during subsequent 
antigen challenge, neighboring Th2 cells produce IL-4 and IL-13 cytokine which signals 
through the HR and causes apoptosis. Herein, we describe the mechanism by which these 
neonatal Th1 cells die. Specifically, IL-4/IL-13 signaling activates STAT6 transcription 
factor which binds to the Stat-binding element in IRF-1’s third intron and acts as an 
enhancer to promote greater IRF-1 expression. IRF-1 then relocates from the nucleus to 
the cytoplasm where it joins Bim in a protein complex to trigger intrinsic apoptosis. 
STAT6 inhibition prevents IRF-1 upregulation and rescues the cells from apoptosis and, 
similarly, silencing of IRF-1 with shRNA just prior to cytokine treatment significantly 
reduced apoptosis. The elucidation of this novel IRF-1-mediated apoptotic pathway may 
provide avenues to block this signaling cascade, prevent Th1 apoptosis, and restore 
neonatal protection against microbes and perhaps even enable successful early life 
vaccination strategies.  
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2. Introduction 
When the field of neonatal immunology was in its infancy, foundational studies described 
early life as a window of time in which tolerance can be induced to prevent later graft 
rejection
9
. In this case, tolerance was considered to be due to the inability of neonates to 
mount an immune response. Since the advent of more sophisticated tools used to dissect 
immune responses, it became clear that neonates do not lack the ability to respond; rather, 
their responses are biased toward Th2 cells and away from Th1 cells
12, 13, 14, 15, 16, 17
. One 
of the critical deficits in neonatal immunity is the inability to mount strong inflammatory 
Th1 responses which are required for pathogen clearance and vaccine protection
172
. 
While it has long been thought that neonates simply don’t have the ability to mount Th1 
responses, we have previously shown that Th1 cells are able to arise alongside Th2 cells 
in the primary response but are susceptible to IL-4/IL-13 cytokine induced death in the 
recall response
144
. This is rather unusual as Th1 cells were originally not thought to 
support IL-4 signal transduction
173
 despite expressing the type I IL-4 receptor which is 
comprised of IL-4Rα and the common γ chain. We found that only in neonates is the type 
II IL-4 receptor (referred to as HR, comprised of IL-4Rα and IL-13Rα1 chains) expressed 
on Th1 cells: a feature that is developmentally controlled by IL-12
104, 174
. Consequently, 
as murine neonates outgrow this developmental window and antigen challenge occurs 
after day 6 of life, they are capable of mounting Th1 secondary responses
104
. This led us 
to question why signaling through the HR in neonatal Th1 cells results in cell death, 
especially that similar signal transduction does not lead to death in other cell types.  
 IL-4 and IL-13 are closely related Th2-associated cytokines critical for the 
development of both allergic and anti-helminth responses. Their receptors and signaling 
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mechanisms contain significant overlap. IL-4 cytokine first binds the IL-4Rα chain which 
then either dimerizes with the common gamma chain or IL-13Rα1 to form either the type 
I or II signaling complex, respectively
175
. IL-13, on the other hand, binds to IL-13Rα1 
which then forms a dimer with either IL-4Rα1 or the decoy chain IL-13Rα2, a non-
signaling receptor
176
. Therefore, the type II IL-4Rα1/IL-13Rα1 HR represents the only 
infrastructure capable of mediating IL-4 and IL-13 signal transduction in neonatal Th1 
cells. Ligand binding of this HR activates receptor-associated Janus kinases, particularly 
JAK1
177
, JAK2
178, 179
, and TYK2 
177, 180
, and downstream signal transducer and activator 
of transcription proteins, mainly STAT6
181
 but also STAT1
182
 and STAT3
183
. How 
signaling through these molecules influences apoptosis has not been previously 
identified.  
In this study we examined the mechanism of IL-4/IL-13 cytokine induced 
apoptosis of neonatal Th1 cells and uncovered a previously unknown IRF-1-mediated 
apoptotic pathway. Using primary murine Th1 cells, we show that engagement of IL-4 or 
IL-13 with the HR on neonatal Th1 cells during secondary antigen challenge leads to 
STAT6 activation and subsequent transcriptional activation of IRF-1 by STAT6. IRF-1 
then translocates to the cytoplasm where it interacts with Bim in a protein complex to 
initiate the intrinsic apoptotic pathway.  
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3. Materials and Methods 
Mice.  
Balb/c mice were purchased from Harlan Sprague Dawley (Indianapolis, IN). 
DO11.10/Rag2
-/-
 transgenic mice which express an OVA-specific TCR have been 
previously described
184
. DO11.10/Rag2
-/-
 IL-13Ra1
-/-
 mice were generated by crossing 
Balb/c IL-13Ra1
-/- 
mice with DO11.10/Rag2
-/-
 mice where the Balb/c IL-13Ra1
-/-
 mice 
were generated in our laboratory as previously described by genetic deletion of exons 7, 
8, and 9
185
. IL-13Rα1+/+-GFP mice, which express green fluorescent protein (GFP) under 
the IL-13Ra1 promoter were generated in our laboratory from in collaboration with 
GenOway (Lyon, France) as previously described
185
. These mice were crossed onto the 
DO11.10 Balb/c background by speed congenics to produce DO11.10 IL-13Ra1-GFP 
reporter mice. C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME). OT-II transgenic mice which express an OVA-specific TCR were a gift from Dr. 
Deyu Fang (Northwestern University, Chicago, IL). C57BL/6 IL-13Ra1
-/-
 mice were 
generated by crossing the Balb/c IL-13Ra1
-/-
 mice to the C57BL/6 background by speed 
congenics as previously described
185
. C57BL/6 OT-II IL-13Ra1
-/-
 mice were generated by 
crossing C57BL/6 IL-13Ra1
-/-
 mice to OT-II mice. All mice were bred and maintained in 
the animal care facility for the duration of the experiments and all experimental 
procedures were performed according to the guidelines of the University of Missouri 
Animal Care and Use Committee. 
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Antigens.  
OVA peptide (SQAVHAAHAEINEAGR) which encompasses amino acids 323-339 of 
the chicken ovalbumin protein was used as a source of antigen as it is immunogenic in 
both Balb/c and C57BL/6 mouse strains. OVAp was purchased from EZbiolab (Carmel, 
IN). Ig-OVA, an IgG2b molecule expressing OVAp within the heavy chain variable 
region has been previously described
186
 and is produced in our laboratory.  
 
Adoptive T cell transfer.  
Total splenic cells (3x10
6
) from 1-d-old DO11.10/Rag2
-/-
 or IL-13R1-/- DO11.10/Rag2-/- 
mice were transferred in sterile PBS into 1-d-old Balb/c mice by iv injection through the 
facial vein using a 30 gauge needle as previously described
186
. To investigate this process 
in C57BL6 recipient mice, 1-d-old OT-II or IL-13R1-/- OT-II mice were used as a 
source of donor cells.  The next day, recipient mice were give ip 100g Ig-OVA in sterile 
PBS.  
 
Analysis of T cell responses. 
Primary/ex vivo. Two weeks after T cell transfer and exposure to Ig-OVA, total splenic 
cells were briefly stimulated for four hours with 10M OVAp and then stained for CD4 
and KJ1-26 (to track DO11.10 cells) or CD4, V5, and V2 (to track OT-II cells). 
Subsequently, cells were fixed in 2% formaldehyde and permeabilized with 0.2% saponin 
and stained for intracellular IFN and IL-4. Flow cytometry analysis was performed on a 
Beckman Coulter CyAn (Brea, CA). 
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Recall. Two weeks after T cell transfer and exposure to Ig-OVA, total splenic cells were 
stimulated with 10M OVAp for 48 hours and the amount of cytokine produced was 
quantified by ELISA whereas the number of cytokine producing cells was determined by 
ELISPOT (see below for details). Additionally, apoptosis of Th1 cells was assessed by 
Annexin V staining. Briefly, splenic cells were stimulated for 4 hours with 10M OVAp 
and then given Brefeldin A at 10g/ml for an additional 8 hours. Surface molecules were 
stained as described above to track DO11.10 or OT-II cells and then cells were 
resuspended in Annexin V binding buffer and PE-conjugated Annexin V was added and 
incubated for 15 minutes at RT. Cells were then washed, fixed, permeabilized, and 
stained for intracellular IFN as described above. Flow cytometry analysis was performed 
on a Beckman Coulter CyAn (Brea, CA). 
Secondary. Two months after T cell transfer and exposure to Ig-OVA, the mice were 
challenged with 125g OVAp emulsified in CFA. Ten days later, total splenic cells were 
stimulated with 10M OVAp for 24 hours and the amount of cytokine produced was 
quantified by ELISA whereas the number of cytokine producing cells was determined by 
ELISPOT. 
 
ELISA and ELISPOT. 
ELISA. IL-4 and IFN production was measured using the standard BD biosciences 
protocol (San Jose, CA) using anti-cytokine antibodies with the following modifications: 
capture buffer, 0.1M NaHCO3; blocking buffer, 3%BSA/PBS; ABTS as substrate. The 
OD450 was read on a SpectraMax 190 counter (Molecular Devices, Sunnyvale, CA) and 
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analyzed using SOFTmax PRO 3.1.1 software where cytokine concentrations are 
extrapolated from the linear portion of a standard curve.  
ELISPOT.  HA multiscreen plates (Millipore, Bedford, MA) were coated with capture 
antibody diluted in 1M NaHCO3 overnight, washed 3x in PBS, and blocked with serum-
containing media for 1 hour before stimulating 1x10
6
 spleen cells/well with 10M OVAp 
at 37°C for 48 hours. Plates were then washed thoroughly and secondary biotinylated 
antibodies diluted in 3%BSA/PBS were added and kept overnight at 4°C. The next day, 
plates were washed and incubated at 37°C for 1 hour with avidin peroxidase and then 
developed by washing and adding the AEC + hydrogen peroxide substrate buffer. Spots 
were imaged on a Cellular Technology Ltd Analyzer series 3B (Cleveland, OH) and 
counted using Immunospot software version 3.2 (Cellular Technology, Cleveland, OH). 
 
Cell Sorting. 
Splenocytes from 1-3 day old DO11.10 IL-13Ra1-GFP neonates were stimulated with 
10M OVAp for 20-24 hours. Cells were collected and washed to rid of free antigen, 
replated, and incubated for an additional 72 hours. Cells were collected again, stained 
with fluorescently labelled antibodies specific for CD4 and CD11c and HR
+
 neonatal Th1 
cells were based on CD11c
-
CD4
+
GFP
+
. The CD11c
-
CD4
+
GFP
-
 population was sorted as  
HR
-
 control and CD11c
+
GFP
+
 cells were sorted as a source of neonatal DCs. Cells were 
sorted on a Beckman Coulter MoFlo (Brea, CA) and only sorts yielding >95% purity 
were used for experiments.  
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Analysis of T cell death. 
After sorting purified populations, T cells were stimulated with 10M anti-CD3e clone 
145-2C11 and 1M anti-CD28 clone 37.51 (referred to as “antigen”) with the addition of 
5 units of either rIL-4 or rIL-13 for 24 or 48 hours. Cells were then collected and stained 
with 7-AAD for 10 minutes in the dark and immediately analyzed using a Beckman 
Coulter CyAn (Brea, CA).  
 
Western blots. 
Sorted HR
+
 CD4 T cells were stimulated with Ag and cytokine for the indicated amount 
of time and then collected, pelleted, and the supernatant removed. Cells were 
resuspended with ice cold RIPA buffer supplemented with protease and phosphatase 
inhibitors and kept on ice for 30 minutes with occasional agitation. The volume of sample 
was adjusted for equivalent cells/ml between stimulation groups. Samples were 
centrifuged at 12000rpm for 15 minutes and the supernatant transferred to a new tube and 
4x loading buffer supplemented with 10% BME was added and the sample heated at 
95°C for 5 minutes.  Proteins were separated on a 4-12% SDS-PAGE NuPage gel and 
transferred to a PVDF membrane. The membranes were blocked in 5% BSA/TBST and 
incubated overnight with primary rabbit antibodies from Cell Signaling Technologies 
(Danvers, MA) diluted in 5% BSA/TBST. The next day, membranes were washed 4x 5 
minutes each in TBST and then incubated at RT for 1 hour with secondary anti-rabbit-
HRP antibody (CST, Danvers, MA). Membranes were washed again and LI-COR 
WesternSure Premium substrate (Lincoln, NE) was added just prior to imaging on a LI-
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COR Odyssey Fc. Densitometry was analyzed with ImageStudioLite v5.2 software 
(Lincoln, NE).  
 
Inhibitor Treatment 
Sorted HR+ CD4 T cells were pretreated for one hour with small molecule inhibitors of 
STAT molecules before the addition of antigen and cytokines. The STAT1 inhibitor was 
2.5M Fludarabine (Selleckchem, Houston, TX), the STAT3 inhibitor was 100M S3I-
201 (Selleckchem, Houston, TX) and the STAT6 inhibitor was 200nM AS1517499 
(Axon Medchem, Reston, VA).  
 
RT-qPCR. 
After stimulation, RNA was isolated from cells with Trizol extraction and ethanol 
precipitation. Quantitative RT-PCR was performed using the Power SYBR Green RNA-
to-CT 1-Step Kit on a StepOnePlus thermocycler (both from Applied Biosystems, Foster 
City, CA). 
 
shRNA silencing. 
Three different 29mer shRNA molecules targeting murine IRF-1 were designed using the 
RNAi Central program offered by the Hannon Laboratory at Cold Springs Harbor Labs 
(http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA). Sequences were chosen 
that do not have homology with other regions in the murine genome. A scrambled non-
specific sequence was also designed. Sequences were engineered to express the human 
U6 promotor as well as a loop containing the Sma1 restriction site between the two 
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palindromic sequences. Full sequences containing restriction sites, promoter, shRNA 
palindromes separated by 8nt loop, and transcription end site are as follows (5’3’):  
#1:AAAGCGGCCGCTTGTGGAAAGGACGAAACACCTGCAGATTAATTCCAACC
AAATCCCAGGGACCCGGGACCCTGGGATTTGGTTGGAATTAATCTGCATTTTT
ATCGAT, #2:AAGCGGCCGCTTGTGGAAAGGACGAAACACCCATCGAGGAAGT 
GAAGGATCAGAGTAGGAACCCGGGATCCTACTCTGATCCTTCACTTCCTCGAT
GTTTTTATCGAT, #3:AAAGCGGCCGCTTGTGGAAAGGACGAAACACCCACTGT 
CACCGTGTGTCGTCAGCAGCAGTACCCGGGAACTGCTGCTGACGACACACGG
TGACAGTGTTTTTATCGAT Scrambled:AAAGCGGCCGCTTGTGGAAAGGACGA 
AACACCGCGCACACCACATTAGTTCGTAGAACTAAACCCGGGATTAGTTCTA
CGAACTAATGTGGTGTGCGCTTTTTATCGAT. Ultramer oligos for each of these 
full length sequences were purchased from IDT (San Jose, CA) and used as template in a 
PCR amplification with the following primers: 
Common Fwd: 5’-AAAGCGGCCGCTTGTGGAAAG-3’ 
#1Rev: 5’-ATCGATAAAAATGCAGATTAATTCCAACCAA-3’ 
#2Rev: 5’-ATCGATAAAAACATCGAGGAAGTGAAGG-3’ 
#3Rev: 5’-ATCGATAAAAACACTGTCACCGTGTG-3’ 
Scrambed Rev: 5’-ATCGATAAAAAGCGCACACCACATTAG-3’ 
These PCR products were T-A cloned into pUC19 Sma1 site for propagation. Upon 
confirmation by Sanger sequencing using the common M13 primers, these constructs 
were individually cloned into the MSCV-IRES-Thy1.1 retroviral vector using Not1 and 
Cla1 restriction sites and retroviral particles were made by cotransfecting 293FT cells 
with the retroviral vectors along with pEco packaging vector using Lipofectamine 3000 
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(Invitrogen, Carlsbad, CA).  Culture supernatants were used to spin transduce freshly 
sorted HR
+
 CD4 T cells. After 2.5 days, cells were stimulated with Ag and cytokine for 
24 hours and IRF1 levels, as well as Annexin V staining, was assessed on Thy1.1
+
 
transduced cells.  
 
ChIP 
After cell sorting and stimulation, cells (100,000 cells per stimulation group) were fixed 
and proteins crosslinked with 1% formaldehyde and 10% serum for 10 minutes shaking 
at RT. 0.125M glycine was added for 5 minutes to stop fixation. Cells were then washed 
twice and lysed for 10 minutes on ice with SDS lysis buffer supplemented with protease 
inhibitors. Samples were diluted to 400µl in 1x ChIP buffer (CST, Danvers, MA) plus 
protease inhibitors and sonicated on a Misonix 3000 sonicator (Power 5, 5 cycles of 15s 
“on” 60s “off”) with the tube submerged in a wet ice bath to produce chromatin 
fragments 150-500bp. Sonicated samples were clarified by centrifugation at 12,000rpm 
for 10 minutes and supernatant transferred to a new tube. To preclear the lysates, 30µl 
protein G magnetic beads (CST) were added and samples rotated at 4°C for 2 hours and 
after magnetic pelleting, chromatin samples were again transferred to a new tube. 5% of 
the sonicated chromatic was withheld and kept at -20°C to be used later in the percent 
input calculation. The remaining chromatin was incubated at 4°C rotating with either 
STAT6 antibody or rabbit IgG isotype overnight. The next morning, magnetic beads 
(CST) were added for an additional 2 hours and then pelleted, the samples washed 3 
times in low salt buffer, 1time in high salt buffer, and finally eluted in ChIP elution buffer 
(all buffers from CST SimpleChIP kit) for 30 minutes at 65°C with agitation. All samples 
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were proteinase K digested to reverse crosslinking and the DNA purified with ChIP DNA 
Clean and Concentrator kit (Zymo, Irvine, CA). The eluted and purified DNA was used 
as a template in PCR reactions to amplify specific STAT6 binding sites. The GRCm38.p5 
murine genome assembly was used to assess binding sites and, specifically, the IRF-1 
transcript ID: Irf1-001 ENSMUST00000108920.8 was chosen as this transcript is the 
largest and includes all of the regions in other transcripts. Binding sites were identified by 
assessing the entire IRF1 gene starting 2kb upstream of the transcription start site for the 
STAT6 consensus sequence TTC(N3-4)GAA which yielded four sites: within the 
promoter (-1357 to -1365 from translation start site), exon (1570-1579), intron (1895-
1903), or 3’UTR (6491 to 6499) regions of the IRF1 gene. Primers were designed to 
flank these regions amplify and are as follows (5’3’): Promoter Fwd: 
CTTTCCAAGACAGGCAAGG, Promoter Rev: AACACTTAGCGGGATTCC, Exon 
Fwd: TCAGCCTTTTCCCATACTTG, Exon Rev: CGGAACAGACAGGCATC, Intron 
Fwd: TGCAGAATTACTGGAGCAG, Intron Rev: 
TTGAGAAAGGAAGATGGAAGTC, 3’UTR Fwd: GATCCTCAGGGAGAGCAG, 
3’UTR Rev: TCAGAGGCAGGCAGAG. Real-time PCR reactions were performed using 
the SYBR Green Universal Master Mix (Applied Biosystems, Foster City, CA) and % 
Input was calculated as follows: % Input = 5% x 2
(C[t]5% Input sample - C[t]IP sample)
.  
 
Co-Immunoprecipitation.  
Sorted HR
+
 CD4 T cells were stimulated for 24 hours with Ag and IL-4 or IL-13 and then 
collected, pelleted, and supernatants removed. Cells were resuspended in ice cold RIPA 
buffer supplemented with protease and phosphatase inhibitors and kept on ice for 30 
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minutes with occasional agitation. Lysates were centrifuged at 12000 rpm for 15 minutes 
and supernatants transferred to a new tube. Samples were pre-cleared with rabbit IgG 
rotating at 4°C for 4 hours before protein G sepharose beads (Invitrogen, Carlsbad, CA) 
were added for an additional 2 hours and then centrifuged at 2000 rpm for 3 minutes and 
the cleared lysates transferred to a new tube. Lysates were incubated with anti-Bim or 
anti-IRF1 antibodies from CST (Danvers, MA) diluted in RIPA buffer overnight rotating 
at 4°C. The next morning, protein G bead slurry was added and rotating continued for 3 
hours. Samples were centrifuged at 2000 rpm for 3 minutes and supernatant was removed 
and kept for an additional immunoprecipitation with beta-tubulin. Beads were washed 3x 
in wash buffer and eluted by heating beads in protein gel loading buffer supplemented 
with 10% BME at 95°C for 5 minutes. Proteins were detected by western blot as 
described above.  
 
Confocal microscopy 
Sorted HR
+
 CD4 T cells were stimulated with Ag and cytokine for 24 hours, collected, 
diluted to 200µl with PBS and spun onto glass slides using a StatSpin Cytofuge 2 (Iris 
Sample Processing, Westwood, MA) at 850rpm for 4 minutes Slides were immediately 
placed into ice cold methanol for 20 minutes at -20°C and then stored dry at the same 
temperature. Slides were then rehydrated in PBS 3x for 5 minutes at RT and blocked in 
5% BSA/PBS for 2 hours at 4°C. After washing in PBS, primary antibody (anti IRF1 
from CST and Alexa647-conjugated anti Bim from Novus) diluted in 1% BSA/PBS was 
added and incubated at 4°C overnight in a moist chamber. The next day slides were 
washed 5x in PBS and incubated with secondary antibody (Anti rabbit Alexa555 from 
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CST) for 1 hour at 4°C. After washing 5x in PBS again, Fluoroshield mounting medium 
with DAPI (Abcam, Cambridge, UK) was added and slides were coverslipped and kept at 
4°C until imaged. All images were acquired on a Leica TCP SP8 confocal microscope at 
63x magnification and processed with LAS X software (Leica, Wetzlar, Germany).  
 
Yeast-two-hybrid 
Assessment of Bim and IRF1 interaction was performed using the ProQuest Two-Hybrid 
System (Invitrogen, Carlsbad, CA). To generate IRF-1, Bim, and Bcl-2 sequences, 
mRNA was isolated from a Balb/c mouse spleen, cDNA synthesized using RevertAid 
First Strand Synthesis cDNA kit (Thermo) and amplified by PCR using primers that 
include attB sites, Shine-Dalgarno, and Kozak sequences as follows (5’3’):  
IRF1 fwd: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAAC 
CATGCCAATCACTCGAATGCGGATGA 
IRF1 rev: GGGGACCACTTTGTACAAGAAAGCTGGGTCCTATGGTGCACAAGGA 
ATGGCCTGA 
Bim fwd: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAAC 
CATGGCCAAGCAACCTTCTGATGTAA 
Bim rev: GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAATGCCTTCTCCATA 
CCAGACGG 
Bcl-2 fwd: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAAC 
CATGGCGCAAGCCGGGAGAACAGGGT 
Bcl-2 rev: GGGGACCACTTTGTACAAGAAAGCTGGGTTCACTTGTGGCCAGGTA 
TGCACCC. 
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Entry clones were generated in pDONR plasmid by BP recombination using Gateway 
Technology Clonase II kit (Invitrogen) and sequences confirmed by automated 
sequencing. Bait and prey plasmids were then generated in pDest32 by LR 
recombination. MAV203 yeast cells were transformed with different combinations of bait 
and prey plasmids and transformants were assessed for protein-protein interaction by -
galactosidase assay, growth on plates lacking uracil, and growth on plates with 5FOA as 
described in the manual.  
Quantitative liquid culture -galactosidase assay was performed by growing the 
transformants in YPD medium until mid-log phase, recording the OD600, lysing the cells 
by rapid freeze/thaw cycles in Z buffer, adding ONPG at 37°C and measuring the elapsed 
time until yellow color developed as well as the OD420. β-galactosidase units were 
calculated by the following: units = 1,000 x OD420 / (time x volume of cells x OD600). 
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4. Results  
A. HR signaling provokes neonatal Th1 cell apoptosis during secondary antigen 
challenge in two different strains of mice. 
The primary response of neonates elicits balanced Th1 and Th2 immunity in both Balb/c 
and C57BL/6 mouse strains (Figure 2.1A). In order to investigate the murine primary 
response, a neonate-to-neonate adoptive transfer system was used
104, 119, 144, 174, 186
. 
Briefly, spleen cells from either HR
+/+
 or HR
-/-
 DO11.10 OVA-specific TCR transgenic 
1d-old mice were transferred i.v. to 1d-old Balb/c hosts or HR
+/+
 or HR
-/-
 OT-II OVA-
specific TCR transgenic splenocytes were transferred i.v. to C57BL/6 neonatal mice. The 
next day, the neonatal recipients were given Ig-OVA and ex-vivo responses were 
measured 14 days later. In both Balb/c and C57BL/6 strains, equivalent frequencies of 
IFNγ-producing Th1 cells and IL-4-producing Th2 cells were detected by intracellular 
staining, regardless of whether the donor cells were from HR
+/+
 or HR
-/-
 mice (Figure 
2.1A). However, analysis of the recall response indicates that, regardless of strain, mice 
that received HR
+/+
 cells have a shift toward Th2 responses with increased IL-4 
production and diminished IFNγ responses compared to mice that received HR-/- cells as 
detected by ELISPOT and ELISA (Figure 2.1B). This indicates that the HR, which is 
present only on Th1 cells during the neonatal stage
144
, has an active role in suppressing 
Th1 responses. This skewing is still evident in the secondary response when neonatal 
recipients of transgenic T cells and Ig-OVA challenge are re-challenged with OVAp/CFA 
at 8 weeks of age (Figure 2.1C). A previous study indicated that the HR directs apoptosis 
of Th1 cells during a second antigen encounter
144
. Here, we demonstrate that HR ablation 
reduces death of Th1 cells at the recall response and that this phenomenon also occurs in 
55 
 
 
 
C57BL/6 neonates (Figure 2.1D). Overall, the results indicate that neonates mount a 
primary response with balanced Th1/Th2 cells but that Th1 cells, which express the HR, 
undergo apoptosis during re-challenge which leads to the well-defined Th2-skewed 
immunity of neonates. 
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Figure 2.1. HR signaling provokes neonatal Th1 cell apoptosis during secondary 
antigen challenge in two different strains of mice. Neonatal Balb/c (left) or C57BL/6 
(right) mice recipient of spleen cells from 1d-old HR
-/-
 or HR
+/+
 DO11.10 (given to
Balb/c) or OT-II (given to C57BL/6) donor mice were given i.p. Ig-OVA the day after 
transfer and ex vivo (A), recall (B and D), and secondary (C) responses were analyzed.  
(A) 14 days after Ig-OVA injection, intracellular IFNγ and IL-4 production by CD4+KJ1-
26
+
 DO11.10 T cells (Balb/c) and by CD4
+
 Vα5high Vα2high OT-II T cells (C57BL/6) are
shown as representative dot plots and combined results are presented from at least 3 
independent experiments. Each bar represents mean ± SEM.  (B) Recall IFNγ and IL-4 
responses after in vitro stimulation with OVAp as measured by ELISPOT (left) and 
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ELISA (right). Each bar represents mean ± SEM from at least three independent 
experiments (C) Two months after spleen cell transfer and Ig-OVA injections, mice were 
challenged with OVAp/CFA and ten days later IFNγ and IL-4 responses were measured 
by ELISPOT (left) and ELISA (right) after in vitro stimulation with OVAp. Bars 
represent mean ± SEM from three independent experiments. (D) OVA-specific Th1 cell 
apoptosis was detected during the recall response by Annexin V staining on CD4
+
KJ1-
26
+IFNγ+ DO11.10 cells (left) or CD4+ Vα5high Vα2high IFNγ+ OT-II cells after in vitro 
stimulation with OVAp. 
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B. Antigen and cytokine signaling are both required for neonatal Th1 apoptosis. 
To better understand how apoptosis of Th1 cells occurs through the HR, we utilized 
DO11.10 IL-13Rα1-GFP reporter mice to sort a pure population of HR-expressing 
neonatal Th1 cells that have already been activated with OVAp in vitro. Since Th1 
apoptosis occurs during the second antigen encounter and is dependent on the HR, we 
sought to determine the extent of TCR stimulation and IL-4 or IL-13 cytokine stimulation 
in apoptosis (Figure 2.2). The results indicate that when HR
+
 cells (GFP
+
) are stimulated 
with antigen, through anti-CD3 and anti-CD28 antibodies, in combination with either IL-
4 or IL-13 cytokine stimulation for 24 hours, significantly more cells die as indicated by 
7-AAD staining in the representative contour plots (Figure 2.2A). This is in contrast to 
unstimulated cells or cells that are treated with either antigen or cytokine alone. 
Conversely, when HR
-
 (GFP
-
) cells are stimulated in the same manner, they fail to 
undergo apoptosis as the 7-AAD staining levels are at background levels (Figure 2.2B). 
Combined results from three independent experiments confirm these findings and also 
demonstrate that even higher levels of apoptosis are evident after 48hr stimulation. 
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Figure 2.2. Antigen and cytokine signaling are both required for neonatal Th1 cell 
apoptosis. HR
+
 Th1 cells were generated by stimulating spleen cells from neonatal 
DO11.10 IL-13Rα1-GFP mice with OVAp for four days and then sorting the CD4+ 
60 
 
 
 
CD11c
-
 GFP
+
 population. These cells were then cultured for 24 hours in the presence or 
absence of 10µM anti-CD3/1µM anti-CD28 antibodies (Ag) with or without the addition 
of recombinant murine IL-4 or IL-13 (5U each) and cell death was measured by 7-AAD 
staining. Panel (A) shows apoptosis on sorted HR
+
 (GFP
+
) cells whereas (B) assesses the 
HR
-
 (GFP
-
) population. (C) Shows combined results after either 24h or 48h incubation 
time. Bars represent mean ± SEM of at least three independent experiments and the * 
above HR
+ 
Ag+IL-4 and HR
+
 Ag+IL-13 bars represent significance both at the level of 
the HR (HR
+
 vs HR
-
) and within the HR
+
 samples they are significantly different from 
the other treatments (Ag, IL-4, and IL-13) but not from each other (Ag+IL4 vs Ag+IL13). 
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C. HR signaling through STAT6 directs Th1 cell death. 
To further delineate the mechanism of apoptosis in neonatal Th1 cells, we began by 
looking at HR-proximal signaling events. Stimulation of murine cells with IL-4 or IL-13 
has been shown to phosphorylate STAT1
182
, STAT3
183
, and STAT6 (Reviewed in 
Hebenstreit et al.
187
). Therefore, we began by assessing phosphorylation of these STAT 
molecules on sorted HR
+
 Th1 cells that were left unstimulated or stimulated with Ag with 
or without IL-4 or IL-13 cytokine. Figure 2.3A shows no significant induction of STAT1 
at either Tyr701 or Ser727 or STAT3 at either Tyr705 or Ser727. However, STAT6 
phosphorylation at Tyr641 was significantly induced upon Ag + IL-4 stimulation. It 
should be noted that Ag + IL-13 treatment resulted in an obvious band on the pSTAT6 
western blot, the levels were not significant when compiled from multiple experiments. 
This is not surprising, though, as IL-13 has a much lower affinity for IL-13Ra1 (Kd 
~30nM
188, 189
) than IL-4 has toward IL-4Ra (Kd 20-300pM
190
 which may contribute to 
the observation that IL-13 is less potent at inducing STAT6 phosphorylation than IL-4 in 
the A549 human alveolar epithelial cell line
189
. In Figure 2.3A, STAT phosphorylation 
was measured by western blot and densitometry used to normalize the bands to total 
STAT levels. Results are compiled from multiple experiments and presented in the bar 
graphs above each blot. If phosphorylation of STAT6 is responsible for HR-mediated 
Th1 apoptosis, then blocking STAT6 through a chemical inhibitor should prevent the 
cells from dying. To test this premise, sorted HR
+
 neonatal Th1 cells were pre-treated 
with chemical inhibitors against STAT1, STAT3, and STAT6, or left untreated, and then 
stimulated with Ag and IL-4 or IL-13 for 48 hours (Figure 2.3B). The results demonstrate 
that blocking STAT1 or STAT3 fails to rescue Th1 cells from dying whereas STAT6 
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inhibition successfully protects Th1 cells as evident by minimal 7-AAD staining. 
Combined results from three independent experiments confirm these findings where only 
the STAT6 inhibitor treated cells have a significantly reduced percentage of 7-AAD
+
 
cells (Figure 2.3C). 
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Figure 2.3. IL-4 and IL-13 activate STAT6 to induce neonatal Th1 cell apoptosis.  
HR
+
 Th1 cells were sorted and stimulated with 10µM anti-CD3/1µM anti-CD28 
antibodies (Ag) with or without the addition of recombinant murine IL-4 or IL-13. (A) 
64 
 
 
 
Cells were collected after 20min to assess phosphorylation levels of STAT1 and STAT3 
or after 1h to measure STAT6 phosphorylation by western blot. The bars represent the 
mean ± SEM of three independent experiments and the * represents statistical 
significance compared to all other stimulation groups as analyzed by one-way ANOVA 
with Bonferroni posttest. (B) Sorted HR
+
 Th1 cells were pretreated with inhibitors 
against STAT1, STAT3, and STAT6 for one hour prior to stimulation. Apoptosis was 
measured by 7-AAD staining after 48h incubation. (C) Combined results from three 
independent experiments carried out as described in (B). Each bar represents the mean ± 
SEM of three independent experiments and the * represents statistical significance when 
compared to the no inhibitor group. 
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D. The intrinsic apoptotic pathway is active during neonatal Th1 cell death.  
Apoptosis is thought to be initiated through either the intrinsic or extrinsic pathways. To 
define which of these pathways are active in neonatal Th1 cell death, we performed gene 
expression analysis of key molecules involved in either pathway (Figure 2.4). The results 
demonstrate that neonatal HR
+ 
(GFP
+
) Th1 cells, but not adult Th1 cells, which do not 
express the HR, or neonatal DCs, which express the HR but do not die when cultured 
with IL-4/IL-13, upregulate expression of Bim, Bax, and Bak which are all involved in 
mitochondrial permeabilization preceding cytochrome c release in the intrinsic apoptotic 
cascade. This upregulation occurs only when cells are stimulated with Ag + IL-4 or Ag + 
IL-13 and not Ag alone indicating a direct role of the HR. Furthermore, there was a 
similar upregulation in FOXO3a, a transcription factor shown to promote Bim 
expression
191
 in the Ag + 4 and Ag + 13 treated HR
+
 neonatal cells. In further support, 
these cells demonstrate lower Akt, which is a negative regulator of FOXO3a
192
. 
Considering extrinsic apoptosis, it has been reported that IRF-1, a transcription factor 
highly expressed in Th1 cells, mediates IFNγ induction of TRAIL193 as well as TCR 
induction of FasL
194
. The results demonstrate that there was no significant upregulation 
of Fas/FasL or TRAIL/DR5 induced by IL-4 or IL-13 signaling but that IRF-1 was, 
surprisingly, upregulated in the neonatal Th1 cells (Figure 2.4). This upregulation was 
also seen at the protein level where sorted neonatal Th1 cells have a basal level of IRF-1 
protein expression that is significantly upregulated in the presence of Ag + IL-4 and Ag + 
IL-13 (Figure 2.5A). 
 
 
66 
 
 
 
 
 
Figure 2.4. Intrinsic apoptotic molecules are upregulated during neonatal Th1 cell 
death. 
HR
+
 (GFP
+
) CD4
+ 
neonatal cells, were sorted and stimulated with 10µM anti-CD3/1µM 
anti-CD28 antibodies (Ag) with or without the addition of recombinant murine IL-4 or 
IL-13 for 24 hours. RNA was isolated and subjected to RT-qPCR of intrinsic (left 
column) or extrinsic (right panel) apoptotic molecules and transcription factors. CD11c
+
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neonatal DCs and adult IFNγ+ CD4+ T cells were tested under the same conditions and 
used for control purposes. mRNA relative quantities (RQ values) were determined by 
normalizing Ct values to the beta-actin internal reference gene.  
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E. STAT6-mediated IRF-1 induction directs apoptosis of neonatal Th1 cells. 
As IRF-1 levels were further incited by the addition of IL-4 and IL-13, we hypothesized 
that the cytokines were signaling through STAT6 to cause IRF-1 upregulation. Indeed, 
this proved to be the case as inhibition of STAT6 with a chemical inhibitor prevented IL-
4 and IL-13-induced IRF-1 upregulation (Figure 2.5B). To assess whether IRF-1 plays a 
role in apoptosis of neonatal Th1 cells, we sought to silence IRF-1 during the Ag + 
cytokine exposure. Since IRF-1 is critical for Th1 polarization, we were not able to use 
an IRF-1-knockout mouse as a source of Th1 cells. Instead, we opted to engineer a 
retrovirus to deliver a cocktail of three IRF-1-shRNA molecules into the sorted Th1 cells 
prior to Ag + cytokine challenge (Figure 2.5C-D and Figure 2.6) allowing Th1 cells to 
develop but silencing IRF-1 during the challenge that normally induces apoptosis. Figure 
2.5C demonstrates that the IRF-1-shRNA treatment significantly reduces IRF-1 protein 
levels in neonatal Th1 cells compared to cells that received nonspecific scrambled 
shRNA control. Furthermore, IRF-1 silencing rescued cells from apoptosis as measured 
by Annexin-V staining (Figure 2.5D). Together, these results highlight a novel role of 
STAT6-mediated IRF-1 induction in the death of neonatal Th1 cells. 
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Figure 2.5. Neonatal Th1 cell death relies on upregulation of IRF-1.  
(A) HR
+
 Th1 cells were sorted and stimulated with 10µM anti-CD3/1µM anti-CD28 
antibodies (Ag) with or without the addition of recombinant murine IL-4 or IL-13 for 24 
hours. Cell lysates were prepared and IRF-1 was measured by western blot. The bar 
graph shows densitometry of IRF-1 normalized to the β-tubulin loading control compiled 
from three independent experiments. (B) shows the level of IRF-1 as measured by 
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western blot and normalized to β-tubulin loading control after cells were pre-incubated 
with a STAT6 inhibitor (AS1517499) for one hour, or left untreated, and then stimulated 
with Ag (10µM anti-CD3/1µM anti-CD28) and either recombinant murine IL-4 or IL-13 
for 24 hours. In (C), sorted HR
+
 Th1 cells were transduced with a retrovirus cocktail 
expressing three different shRNA molecules that target IRF-1 or a scrambled shRNA 
control and then incubated with antigen and cytokine as described in (A). After 24 hours 
cells were collected and analyzed for IRF-1 expression and apoptosis by Annexin V 
staining on Thy1.1
+
 transduced cells. Bars represent the mean ± SEM of at least three 
independent experiments where * is p≤0.05 and ** is p≤0.01. 
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F. STAT6 binds to intron 3 in the IRF-1 gene to promote IRF-1 transcription in 
neonatal Th1 cells. 
The ability of IL-4 and IL-13 to induce, rather than inhibit, IRF-1 through STAT6 is 
rather surprising as previous reports show that IL-4-induced STAT6 antagonizes IRF-1 
expression by competing with STAT1 for access to the STAT binding element (SBE) 
within the IRF-1 promotor
195
. Alternatively, the trans-activation domains of STAT6 may 
directly inhibit IRF-1 transcription in the absence of STAT1 competition
196
 but these 
studies were not performed in primary T cells. To decipher the influence of STAT6 in 
IRF-1 gene expression in murine neonates, we first identified regions in the murine IRF-1 
gene where STAT6 could potentially bind based on the STAT6-binding consensus 
sequence TTC(N3-4)GAA
197
. Figure 2.6A depicts the four sites containing this sequence 
comprising regions in the promotor, exon 3, intron 3, and the 3’ UTR. Chromatin 
immunoprecipitation was performed to determine whether STAT6 binds to each of these 
sites in sorted neonatal Th1 cells stimulated with Ag and IL-4. Following precipitation of 
STAT6, only DNA from the SBE in the intron was able to significantly amplify over that 
bound by the nonspecific IgG control whereas no significant binding was detected in the 
promoter, exon, or 3’ UTR (Figure 2.6B).  To determine how cytokine stimulation affects 
STAT6 binding to the intron SBE, cells were stimulated with either Ag alone or in 
combination with IL-4 or IL-13 before chromatin immunoprecipitation. The results 
demonstrate that STAT6 is mobilized to the intron region only when cells were treated 
with antigen and cytokine together as a significant enrichment (% input) of STAT6 
bound DNA is amplified from Ag + IL-4 and Ag + IL-13 treated cells versus Ag 
treatment alone (Figure 2.6C). Furthermore, IL-13 seems to be even more potent than IL-
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4 at initiating this binding event despite the reduced ability of IL-13 to induce STAT6 
phosphorylation (Figure 2.3A). 
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Figure 2.6. STAT6 binds to intron 3 in the IRF-1 gene to promote IRF-1 
transcription in neonatal Th1 cells. (A) shows a schematic diagram of the murine IRF-
1 gene locus. The stars in the promoter region (P), exon 3 (E3), intron 3 (I3), and the 3’ 
UTR indicate the presence of the STAT6 binding site TTC(N3-4)GAA. In (B) and (C), 
sorted neonatal Th1 cells were stimulated for 40 minutes in the presence of antigen and 
IL-4 (B) or Ag with or without IL-4 or IL-13 (C) and subjected to chromatin 
immunoprecipitation with either anti-STAT6 antibody or IgG isotype control. The 
precipitated chromatin was then amplified by qPCR with primers to encompass the four 
putative binding sites (B) or just the intron region (C). Data are represented as percent 
input. 
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G. IRF-1 and Bim co-immunoprecipitate and localize to the cytoplasm during 
neonatal Th1 apoptosis. 
The increase in IRF-1 during Ag and cytokine challenge didn’t appear to regulate any of 
IRF-1’s downstream targets in the extrinsic pathway such as TRAIL or FasL (Figure 2.4) 
so we hypothesized that IRF-1 plays a role in modulating the intrinsic apoptotic pathway. 
Prior reports demonstrate that a virally-encoded IRF-1 (HHV8 vIRF1) displays homology 
with cellular IRF-1
198, 199, 200
 and the two share several binding partners such as p300 and 
IRF-8
201, 202
. Since HHV8 vIRF1 is known to bind and regulate the cellular localization of 
the intrinsic apoptotic molecule Bim
203
, we questioned whether murine IRF-1 may also 
bind Bim to initiate apoptosis of neonatal Th1 cells. To this end, sorted Th1 cells were 
left unstimulated or stimulated with either Ag or Ag + IL-4 or IL-13 and then subjected to 
immunoprecipitation. Upon immunoprecipitation with anti-Bim antibody, lysates from 
cells that had been stimulated with Ag + IL-4 and Ag + IL-13 displayed strong IRF-1 
bands as detected by western blot (Figure 2.7A, upper panel), indicating that Bim and 
IRF-1 exist in a complex together. Control samples were immunoprecipitated and blotted 
with anti-β-tubulin. The reciprocal experiment also holds true where lysates prepared 
from Ag + cytokine treated cells were immunoprecipitated with anti-IRF-1 antibody and 
strong Bim signal was detected by western blot (Figure 2.7A, lower panel). In this case, 
however, Ag + IL-4 treatment appears to be stronger at inducing this interaction than Ag 
+ IL-13. Interestingly, of the three isoforms of Bim, only BimEL was detectable. These 
findings then led us to consider the cellular localization of the Bim/IRF-1 protein 
complex as Bim usually exists in the cytoplasm and IRF-1 is active in the Th1 nucleus. 
Confocal microscopy was used to detect subcellular localization of IRF-1 and Bim in 
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cells treated with Ag with or without IL-4 or IL-13 (Figure 2.7B). Antigen treated cells, 
which do not undergo apoptosis, show Bim staining (green) in the cytoplasm whereas 
IRF-1 (red) is located within the nucleus (DAPI, blue). There is no co-localization when 
the images are merged. On the other hand, cells treated with Ag + IL-4 and Ag + IL-13 
show that IRF-1 relocates to meet Bim in the cytoplasm and the merged image shows co-
localization of Bim and IRF-1 (indicated by yellow color). Additionally, when cells were 
simultaneously treated with a STAT6 inhibitor, IRF-1 levels were reduced and the 
protein failed to localize to the cytoplasm, again supporting the role of IL-4 and IL-13 in 
IRF-1 upregulation and also highlighting the necessity of cytokine signaling in IRF-
1/Bim interaction (Figure 2.7B). Over 100 cells were imaged from two independent 
experiments and data compiled to assess the localization of IRF-1 in each of these 
treatments where location is described as cytoplasmic, nuclear, or spread intermediately 
between the two (Figure 2.8 and Figure 2.7C). While there were cells that displayed 
intermediate localization in each of the treatments, the majority of cells treated with Ag + 
IL-4 or IL-13 displayed cytoplasmic IRF-1 localization. Conversely, in cells that were 
treated with only Ag or when Ag + cytokine treated cells were given STAT6 inhibitor, 
IRF-1 was found to be predominately localized to the nucleus. Together, these results 
demonstrate that IL-4 and IL-13 signaling in neonatal Th1 cells instigate IRF-1 relocation 
to the cytoplasm where it interacts in a complex with Bim. 
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Figure 2.7. IRF-1 and Bim co-immunoprecipitate and localize to the cytoplasm 
during neonatal Th1 apoptosis. (A) Shows co-immunoprecipitation (co-IP) of IRF-1 
and Bim in lysates of neonatal Th1 cells left untreated or stimulated with  Ag alone or in 
the presence of IL-4 or IL-13 for 24 hours. The upper blot shows lysates precipitated with 
anti-Bim antibody and blotted for IRF-1 whereas the lower blot shows lysates 
precipitated with anti-IRF-1 antibody and blotted for Bim. As a loading control, the same 
lysate stock used in the corresponding experiment was used to precipitate and blot for β-
tubulin. (B) Representative confocal microscopy images of neonatal Th1 cells that were 
stimulated as described in (A) and probed for Bim and IRF-1. The bottom two rows 
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depict cells that were treated with a STAT6 inhibitor during stimulation. The scale bars 
represent 5 µm. (C) Compiled data from two independent experiments as described in (B) 
where the localization of IRF-1 is characterized as residing in the cytoplasm, 
intermediate, or nucleus (See Fig. 2.8 for examples). At least 100 cells were analyzed for 
each treatment. 
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Figure 2.8. Examples of cellular localization of IRF-1. Sorted neonatal Th1 cells were 
stimulated with Ag and IL-4 and stained with a fluorescently tagged antibody against 
IRF-1 (red). The left panel shows an example of nuclear localization by IRF-1 where the 
top is IRF-1 only and the bottom is IRF-1 and DAPI together. The middle panel shows 
intermediate IRF-1 localization where some protein is detected in the nucleus and some is 
detected in the cytoplasm. The right panel depicts cytoplasmic IRF-1 localization.  
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H. Bim and IRF-1 do not bind directly in the yeast-two-hybrid assay.  
As Bim and IRF-1 appear to exist in a complex, we questioned whether they bind each 
other directly. To test this, we used the yeast-two-hybrid system. Three different isoforms 
of Bim were fused to the GAL4 DNA binding domain (bait) and IRF-1 was fused to the 
GAL4 DNA activation domain (prey) and transformed into yeast containing LacZ and 
URA3 reporter genes (Figure 2.9). When the transformants were assessed for beta-
galactosidase activity, none of the Bim/IRF-1 combinations resulted in positive-
interacting blue colonies which were evident in the positive controls Krev1/RalGDS-wt 
and Bcl2/BimEL and to a much lesser extent in the weak-positive control 
Krev1/RalGDS-m1 (Figure 2.9A, left column). Similarly, when grown on media lacking 
uracil, only the strong positive control Krev1/RalGDS-wt demonstrated healthy growth 
which was not seen in the other transformants (Figure 2.9A, middle column). The 
addition of 5FOA, a negative selection agent that kills cells expressing URA3, hampered 
the growth of the strong positive control but did not affect the others (Figure 2.9A, right 
column). When these transformants were grown in liquid culture, a quantitative beta-
galactosidase assay revealed a similar trend where only the strong positive Krev1 control 
and Bcl2/BimEL control displayed enzymatic activity but not any of the other 
transformants (Figure 2.9B). These results strongly that Bim and IRF-1 do not directly 
bind each other but likely exist in a complex with other proteins. 
 
 
 
80 
 
 
 
 
Figure 2.9. IRF-1 and Bim do not directly bind one another.  The yeast two-hybrid 
system was used to assess the ability of different isoforms of Bim to bind IRF-1. Three 
different isoforms of Bim, as well as the positive control Bcl-2, were expressed as fusion 
proteins with the GAL4 DNA-binding domain (bait) whereas IRF-1 was fused with the 
GAL4 activation domain (prey). Both fusion proteins were expressed in MaV203 yeast 
strain containing LacZ and URA3 reporter genes downstream of the GAL4 DNA binding 
site. (A) Yeast transformants were assessed for interaction between the bait and prey 
proteins by replicate plating on different media. Positive interactions are indicated by 
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blue color in the beta galactosidase assay as well as the ability of the yeast strains to grow 
on media lacking uracil. The addition of 5FOA provides a method for negative counter 
selection of -URA transformants. The interactions between Krev1 and RalGDS were used 
as a positive control while the m1 mutation of RalGDS provided a weak positive 
interaction and m2 RalGDS serves as a negative control. An additional positive control 
included Bim and Bcl-2 which are known to interact. (B) Quantitative beta galactosidase 
assay was performed in liquid culture. Bars represent the mean ± SD of triplicate wells. 
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5. Discussion 
The neonatal period represents a unique developmental transition where the in utero 
requirement for anti-inflammatory conditions contrasts sharply with the immediate 
demand for pro-inflammatory protection against pathogens upon birth. During 
pregnancy, Th2 cytokines are produced at the fetal-maternal interface and correspond to 
fetal survival
6
. The importance of maintaining an anti-inflammatory environment during 
gestation is further highlighted in studies showing T cells from peripheral blood in 
pregnant women are less capable of producing Th1 cytokines but more likely to make 
Th2 cytokines than in non-pregnant women
204
. Moreover, women with recurrent 
miscarriages have elevated Th1 levels that are similar to non-pregnant women. While this 
anti-inflammatory state is critical for the maintenance of pregnancy, it renders the infant 
susceptible to microbial infection immediately after birth.  
Despite an intrinsic drive for neonatal naïve T cells to become Th2 cells, which 
has been attributed to epigenetic hypomethylation of the Th2 locus
137
, we have 
demonstrated that neonates are indeed capable of mounting Th1 responses but that these 
Th1 cells undergo apoptosis during rechallenge
144
. Understanding the mechanism behind 
this apoptotic pathway may highlight novel ways to prevent cell death and restore Th1 
immunity to combat early life infection and confer enhanced vaccine protection. Herein, 
we define the signaling pathway whereby IL-4 and IL-13 cytokines utilize their shared 
heteroreceptor to divert antigen induced activation of neonatal Th1 cells toward cell 
death.  
83 
 
 
 
In previous studies we utilized the Balb/c strain of mice to investigate Th2 biased 
neonatal immunity
104, 119, 144, 174
. To ensure that our findings were not an artifact of the 
mouse strain, we adapted the neonate-to-neonate transfer model
186
 to the C57BL/6 strain 
where either HR
+/+
 or HR
-/-
 neonatal OVA-specific OT-II cells were transferred into 
neonatal C57BL/6 hosts to enrich the frequency of responding cells and provide a means 
of tracking whether the T cells became Th1 or Th2. Our findings corroborated the results 
from Balb/c mice where Th1 cells do develop in the neonate but they die during recall 
indicating that this phenomenon is not strain specific. Furthermore, we demonstrate that 
this process relies on both antigen and cytokine together to drive apoptosis.  
Prior investigation of IL-4/IL-13 signaling pathways indicate that these cytokines 
have the potential to phosphorylate STAT1, STAT3, and STAT6. Indeed, our lab has 
demonstrated a pivotal role for both STAT6 and STAT1 phosphorylation downstream of 
the HR in lineage choice of early thymic progenitor cells (manuscript under review). 
However, in the context of neonatal Th1 cells, STAT6 is the only operative STAT 
molecule. Interestingly, even though IL-4 induced a much stronger phosphorylation 
signal than IL-13, there is no apparent difference in apoptosis at either 24 or 48 hours, 
indicating that a relatively weak IL-13 signal can still lead to significant apoptosis of Th1 
cells. Furthermore, the chromatin immunoprecipitation assay suggests that antigen and 
IL-13 induces greater STAT6 binding to the intron region of IRF-1than does antigen and 
IL-4, although the difference is not statistically significant. Again, this highlights how 
even a minimal STAT6 phosphorylation event by IL-13 can culminate in a significant 
biological process. There are likely differences in signaling kinetics and possibly even 
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minor deviations in the pathway induced by IL-4 versus IL-13 but these have not been 
identified.  
While this study elucidates a critical role for IRF-1 in the intrinsic apoptosis 
pathway, the mechanism of IRF-1 relocation from the nucleus to the cytoplasm is still 
unknown. It is plausible that HR signaling induces a post-translational modification in 
IRF-1 that aids its nuclear export especially that IRF-1 can be phosphorylated, 
sumoylated, and ubiquitinated. Furthermore, it should be noted that even though Bim and 
IRF-1 do not display direct binding in the yeast-two-hybrid assay it is possible that a 
particular post-translational modification is not occurring in the yeast system which 
would allow direct binding.  
Another interesting consideration is that the induction of intrinsic apoptosis is still 
not completely understood. It is clear, however, that apoptosis is regulated through the 
balance of pro- and anti-apoptotic factors, particularly the various Bcl-2 family proteins, 
at the mitochondrial membrane
205, 206
. Our data indicates that Bim, a pro-apoptotic factor 
is upregulated during antigen and cytokine induced neonatal Th1 death. While this alone 
may have the potential to induce apoptosis, it is likely that IRF-1 is playing more of a 
direct role in tipping the scale toward apoptosis. Evidence for this is presented as the two 
proteins co-immunoprecipitate and localize together outside of the nucleus and shRNA 
silencing of IRF-1 reduces apoptosis. Perhaps IRF-1 allows Bim to be more potent or 
prevents Bcl-2 or other anti-apoptotic proteins to be less effective. Furthermore, the 
subcellular localization of Bim also plays a role in its function. In healthy cells Bim is 
sequestered to the microtubule-associated dynein motor complex and certain apoptotic 
stimuli cause Bim to release from the complex and move to the mitochondria where it is 
85 
 
 
 
able to overpower anti-apoptotic molecules such as Bcl-2 to initiate apoptosis
207
. 
However, in activated T cells Bim is constitutively associated with Bcl-2-related proteins 
on the mitochondria and not found on microtubules
208
. Therefore, IRF-1 may serve as a 
trigger to either promote Bim activity or inhibit Bcl-2 activity. Overall, this study 
provides new insight into the apoptotic pathway of neonatal Th1 cells and highlights a 
role for IRF-1 in the intrinsic apoptotic pathway.  
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 CHAPTER III 
THE ROLE OF THE IL-4/IL-13 HETERORECEPTOR IN 
NEONATAL VACCINATION 
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1. Abstract 
Neonatal immunity is characterized by poor Th1 responses which render the infant 
susceptible to microbial infection and non-responsive to vaccination. Efforts to 
understand poor Th1 immunity may offer insights to novel vaccine strategies. We have 
previously demonstrated that neonatal Th1 cells express the IL-4/IL-13 heteroreceptor 
(HR) which marks them for apoptosis upon later antigen encounter
144
 and that the 
absence of the HR restores Th1 immunity
119
. Here, we extend these findings to the 
context of early life vaccination and provide evidence that the absence of the HR restores 
Th1 and CTL vaccine responses upon LCMV infection. Furthermore, the blockade of 
STAT6 signaling, which is downstream of the HR, similarly allows for improved T cell 
responses. Perhaps the key to unlocking vaccine potential in neonates resides in strategies 
that prevent HR signaling.  
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2. Introduction 
Infections are common during early life and significantly contribute to neonatal 
morbidity and mortality. The lack of immunological memory, in combination with the 
immaturity of immune cells and tissues, contribute to high global infant mortality rates. It 
is estimated that, globally, 2.8 million infants die each year during the neonatal stage and 
that nearly a quarter of these deaths are directly due to infection
7
. While vaccination 
remains the forerunner of infectious disease prevention, such strategies often do not work 
well in neonates due to their limited Th1 responses and overall poor adaptive immune 
function
154
. For this reason, many vaccines are delayed until later in life, such as 
influenza which isn’t given until 6 months of age or MMR and Varicella which are 
delayed until 12 months
167
. Even vaccines that are given earlier in infancy show reduced 
efficacy and several boosters are needed in order to provide sufficient protection as in the 
case of DTaP, Hib, and pneumococcal conjugate vaccine. Despite the physiological 
defects in neonatal immunity, some vaccines are able to illicit powerful responses, such 
as Bacillus Calmette-Guerin vaccine which is effective at birth
167
. This highlights the 
ability of specific antigen/adjuvant combinations to prove useful in neonates and 
significant efforts in vaccine design are aimed at understanding this process along with 
understanding the function of neonatal immune cells.  
 Prior studies performed in our lab discovered a developmental phenomenon that 
renders Th1 cells, which are important for vaccine responses, susceptible to antigen 
induced death. Specifically, Th1 cells from neonatal mice express the type II IL-4 
heteroreceptor (HR), comprised of IL-13Rα1 and IL-4Rα, through with both IL-4 and IL-
13 cytokines can signal
144
. During recall, Th2 cells produce these cytokines which signal 
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through the HR on Th1 cells and lead to their death, thereby perpetuating the neonatal 
Th2 bias. Interestingly, this appears to be a developmental trait that is modulated by IL-
12 as by day 6 of life there are sufficient IL-12-producing DCs to counter the 
upregulation of the HR on Th1 cells and prevent their apoptosis
104
. Recent studies 
highlight the mechanism whereby IL-4/IL-13 induces apoptosis through a novel STAT6-
IRF1 death pathway. It is currently unknown how HR expression on Th1 cells affects 
early life vaccination and if it is possible to restore vaccination capacity by interfering 
with the STAT6-IRF1 signaling pathway.  
 Mice that lack the HR have robust Th1 responses in both the primary and 
secondary responses
119
 so we hypothesized that HR-deficient mice would display 
enhanced responses to neonatal vaccination as compared to wild-type HR-sufficient 
mice. Herein, we report that HR
-/-
 mice have enhanced peptide vaccine responses to an 
acute viral infection induced by lymphocytic choriomeningitis virus (LCMV) Armstrong 
resulting in reduced viral titers as well as enhanced T cell responses when challenged 
with the chronic infection model LCMV Clone 13 as compared to HR-sufficient wild-
type mice. Furthermore, this protective effect is likely due to a defective STAT6-IRF1 
signaling pathway as in vivo inhibition of STAT6 signaling at the time of infection in 
HR-sufficient mice provides restored T cell responses. These findings provide evidence 
that poor vaccine outcomes during the neonatal period are due to HR signaling in Th1 
cells and that blocking the signaling pathway may provide an avenue to restore cell 
function and enhance vaccination.  
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3. Materials and Methods 
Mice. 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  
C57BL/6 IL-13Ra1
-/-
 mice were generated by crossing the Balb/c IL-13Ra1
-/-
 mice to the 
C57BL/6 background by speed congenics as previously described
185
. All mice were bred 
and maintained in the animal care facility for the duration of the experiments and all 
experimental procedures were performed according to the guidelines of the University of 
Missouri Animal Care and Use Committee. 
 
Antigens.  
Lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) amino acid residues 33-
41 (GP33, KAVYNFATC) is an H2-D
b 
restricted antigen recognized by CD8 T cells. GP 
61-80 (GP61, GLKGPDIYKGVYQFKSVEFD) is a CD4 I-A
b
 restricted antigen. Both 
peptides were obtained from EZBiolab (Carmel, IN) and used in immunization and ex 
vivo stimulation for analysis of T cell responses. LCMV strains Armstrong and Clone13 
were propagated in lab and used to infect mice after immunization. Both virus strains 
were a gift from Dr. Bumsuk Hahm (University of Missouri, Columbia, MO).   
 
Immunization and Infection. 
Neonatal C57BL/6 and C57BL/6 IL-13Ra1
-/-
 mice were given a peptide vaccine 
consisting of 10µg each of GP33 and GP61 in 50% IFA (100µl volume) intraperitoneally 
(IP) at three days of age. 7-8 weeks later the mice were then infected with either 2x10
5
 
PFU of LCMV Armstrong given IP or 2x10
6
 PFU LCMV Clone13 administered IV. In 
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the case of Armstrong infection, mice were sacrificed four days later and T cell responses 
as well as viral titers in spleen, kidney, liver, and lung were measured. Regarding 
Clone13 infection, serum was collected from mice weekly until sacrifice at 46 days post 
infection when T cell responses were measured along with virus titers from serum, 
spleen, kidney, liver, and lung.  
 
Analysis of T cell responses. 
Total splenic cells were stimulated for six hours with 1g/ml GP33, 5µg/ml GP61, and 
BFA. Cells were then stained for CD4, CD8, GP33-specific tetramer, and GP61-specific 
tetramer to track antigen specific T cells. Subsequently, cells were fixed in 2% 
formaldehyde and permeabilized with 0.2% saponin and stained for intracellular IFN, 
TNFα, and IL-4. Flow cytometry analysis was performed on a BD LSR-Fortessa X-20 
(Franklin Lakes, NJ). LCMV GP-specific tetramers were obtained through the NIH 
Tetramer Core Facility (Atlanta, GA) 
 
Analysis of Viral Titers. 
Viral titers were determined by plaque assay on Vero E6 cells (ATCC, Manassas, VA). 
Briefly, Vero cells were grown to confluency in 6-well plates and infected with various 
dilutions of homogenized tissue samples in culture media for 90 minutes at 37°C with 
gentle rocking every 15 minutes. Samples were then aspirated out of the wells and 
overlayed with agarose + EMEM and incubated at 37°C. 7 days later, samples were fixed 
with formaldehyde, the agarose overlay removed and stained with crystal violet to 
visualize plaques.  
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In vivo inhibition of STAT6. 
Mice were given daily IP injections of the STAT6 inhibitor AS1517499 (Axon 
Medchem, Reston, VA) at a dose of 10mg/kg in a 60µl volume of 50% DMSO/PBS for 6 
days total.  
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4. Results 
A. Neonatal peptide vaccination induces protective immunity against acute infection 
by lymphocytic choriomeningitis virus.  
As IL-4 and IL-13 induce apoptosis of neonatal Th1 cells, we questioned the functional 
consequence of HR signaling in neonatal vaccination. LCMV was chosen as the infection 
model because it is well-characterized and includes both acute and chronic strains. There 
are also many reagents and tools already developed in which to analyze the LCMV 
response such as tetramers that can be used to track antigen-specific T cells. The success 
of neonatal vaccination depends on the context of antigen type, dose, and adjuvant used 
and we therefore first sought to define a successful vaccine regimen that would allow 
analysis of the response. We chose a peptide vaccine comprised of both CD4 and CD8 
epitopes to induce maximal response. Neonatal HR
+/+
 or HR
-/-
 C57BL/6 mice were given 
an IP peptide vaccine of LCMV GP33-41 and GP61-80 emulsified in IFA. Two months 
later the mice were challenged with 2x10
5
 pfu LCMV Armstrong (Arm), which causes 
acute viral infection, and titers were measured 4 days later in spleen, kidney, liver, and 
lung. In both HR
+/+
 and HR
-/-
 mice, vaccination resulted in decreased viral titers in the 
spleen, kidney, liver and lung as compared to mice given a null vaccine which consisted 
of IFA alone (Figure 3.1).  Each group consisted of 9 mice from two separate 
experiments. While results were statistically significant in the kidney and liver for the 
HR
+/+ 
mice, the difference appeared to be greater in the HR
-/-
 mice in the spleen and liver 
and, most surprisingly, no virus could be detected in the lungs of vaccinated HR
-/-
 mice.  
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Figure 3.1. Neonatal vaccination provides protection against later LCMV challenge 
in both HR
+/+
 and HR
-/-
 mice.  
Neonatal IL-13Rα1+/+ (HR+/+) or IL-13Rα1-/- (HR-/-) C57BL/6 mice were immunized IP 
with 10µg each of LCMV GP33-41 and GP61-80 peptides in IFA (Vaccinated) or IFA 
alone (Nil) at 3 days of age. Seven weeks later, mice were infected IP with LCMV Arm 
at 2x10
5
 pfu. Four days post infection, viral titers from various organs were quantified by 
plaque assay on Vero cells. 
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B. The absence of the HR confers enhanced vaccine protection in neonatal mice. 
Following the immunization and infection model established above, we then sought to 
compare whether HR-deficiency affects neonatal vaccine protection against acute LCMV 
infection. Accordingly, three-day old HR
+/+
 or HR
-/-
 C57BL/6 mice were given an IP 
peptide vaccine of LCMV GP33-41 and GP61-80 emulsified in IFA. Two months later 
the mice were challenged with 2x10
5
 pfu LCMV Arm and titers were measured 4 days 
later in spleen, kidney, liver, and lung. Results are combined from 9 mice per group from 
two different experiments. The results demonstrate that wild-type mice in which HR 
signaling is intact display significantly higher viral titers in the spleen and liver (Figure 
3.2). Again, there were undetectable levels of virus in the lungs of HR-deficient mice 
which further supports the hypothesis that HR-deficiency will enhance vaccine responses.  
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Figure 3.2. HR
-/-
 mice respond better to neonatal LCMV vaccination than HR
+/+
 
mice.  
Neonatal IL-13Rα1+/+ (HR+/+, shaded bars) or IL-13Rα1-/- (HR-/-, open bars) C57BL/6 
mice were immunized IP with 10µg each of LCMV GP33-41 and GP61-80 peptides in 
IFA (Vaccinated) or IFA alone (Nil) at 3 days of age. Seven weeks later, mice were 
infected IP with LCMV Arm at 2x10
5
 pfu. Four days post infection, viral titers from 
various organs were quantified by plaque assay on Vero cells. 
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C. Increased vaccination efficacy of HR-deficient mice is not due to enhanced T cell 
responses after acute viral infection.  
Given that HR-deficient mice have enhanced Th1 immunity relative to HR-sufficient 
mice
119
 and that HR-deficiency confers enhanced vaccine responses, we hypothesized 
that HR-deficient mice would display enhanced T cell responses. Further evidence for 
this hypothesis stems from our findings that signaling through the HR in neonatal Th1 
cells leads to their apoptosis and therefore ablation of signaling capacity would spare Th1 
cells from death and allow to them to respond accordingly. To test this hypothesis, we 
immunized three-day old HR
+/+
 or HR
-/-
 C57BL/6 mice with a GP33-41/GP61-80 peptide 
vaccine. Two months later the mice were challenged with 2x10
5
 pfu LCMV Arm and 
splenic T cell responses were analyzed four days after infection by surface and 
intracellular staining with flow cytometry. Results are combined from 9 mice per group 
from two different experiments. Surprisingly, there was no difference in the frequency of 
antigen-specific CD4
+
 or CD8
+
 T cells as measured by GP61 or GP33 tetramer staining, 
respectively (Figure 3.3, top panel). Furthermore, when we assessed intracellular 
cytokine production after brief ex vivo stimulation with BFA, we found that both the 
HR
+/+
 mice and the HR
-/-
 mice produced similar levels of IFNγ and TNFα in their CD4+ T 
cells (Figure 3.3, left side two bottom panels) and CD8
+
 T cells (Figure 3.3, right side 
two bottom panels). These results indicate that enhanced vaccine-mediated protection to 
the acute virus in HR
-/-
 neonates may occur through a mechanism independent of T cells.  
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Figure 3.3. The HR does not play a role in T cell responses to LCMV Armstrong 
infection after neonatal vaccination.  
Neonatal IL-13Rα1+/+ (HR+/+, shaded bars) or IL-13Rα1-/- (HR-/-, open bars) C57BL/6 
mice were immunized IP with 10µg each of LCMV GP33-41 and GP61-80 peptides in 
IFA (Vaccinated) or IFA alone (Nil) at 3 days of age. Seven weeks later, mice were 
infected IP with LCMV Arm at 2x10
5
 pfu. Four days post infection, splenic cells were 
stimulated briefly with GP33/61 peptides in the presence of BFA, stained with GP33/61-
specific tetramers and intracellular cytokines were detected by flow cytometry.  
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D. HR
-/- 
neonates display enhanced T cell vaccine responses upon chronic LCMV 
Clone 13 infection.  
As the HR does not play a role in T cell responses to acute viral infection in immunized 
neonates we questioned whether the situation may be different in a chronic infection with 
LCMV Clone 13 (Cl13), especially since CD8
+
 CTLs rely on CD4
+
 T cell help during 
chronic infection
209
. To this end, we immunized neonatal HR
+/+
 or HR
-/-
 C57BL/6 mice 
with the same peptide vaccine used in the Armstrong studies: 10µg each of GP33 and 
GP61 peptides in IFA. Two months later, the mice were infected IV with 2x10
6
 pfu of 
LCMV Cl13 and splenic T cell responses were measured 46 days post infection. In 
contrast to infection with Armstrong, HR
-/-
 mice displayed increased frequency of 
GP61
Tet+
 CD4
+
 T cells relative to HR
+/+
 mice (Figure 3.4, upper left panel) indicating a 
heightened CD4 T cell response to vaccination. Furthermore, a greater percentage of CD4 
T cells from HR
-/-
 mice produced IFNγ and TNFα (Figure 3.4, left panels) than their 
HR
+/+
 counterparts demonstrating an increased functional capacity afforded when HR 
signaling is non-functional. As CD4 T cells are critical for sustaining CTL responses 
during a chronic infection which ultimately leads to viral clearance, we also assessed the 
CD8
+
 T cell response. Indeed, HR
-/-
 mice have a greater frequency of GP33
Tet+
 CD8
+ 
T 
cells as compared to those from HR
+/+
 mice (Figure 3.4, upper right panel). Yet, despite 
the enhanced frequency of antigen-specific CD8 responders, there was no difference 
between HR
-/-
 and HR
+/+
 regarding the functional capacity of CD8 cells to produce IFNγ 
or TNFα (Figure 3.4, right panels). It should be noted that this preliminary experiment 
included only two mice and therefore statistical analyses have not been applied.  
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Figure 3.4. HR
-/-
 neonatal mice have enhanced Th1 vaccine responses upon chronic 
LCMV Clone 13 infection to support the generation of CTLs.  
Neonatal IL-13Rα1+/+ (HR+/+, shaded bars) or IL-13Rα1-/- (HR-/-, open bars) C57BL/6 
mice were immunized IP with 10µg each of LCMV GP33-41 and GP61-80 peptides in 
IFA (Vaccinated) or IFA alone (Nil) at 3 days of age. Eight weeks later, mice were 
infected IV with 2x10
6
 pfu LCMV Cl13. At 46 days post infection, mice were sacrificed 
and splenic CD4
+
 T cell responses were measured after ex vivo stimulation with GP33/61 
peptides. Data are compiled from 2 mice from a single experiment and therefore no 
statistics were performed.  
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E. Inhibition of STAT6 signaling rescues T cell function and allows successful 
vaccination in neonatal mice.  
Previous studies (see Chapter II) have demonstrated that signaling through the HR 
underpins the function of Th1 cells during the neonatal period and that this signaling 
pathway, induced by both IL-4 and IL-13, proceeds through STAT6 activation. Indeed, 
silencing of STAT6 with a pharmacological inhibitor prevents Th1 cell apoptosis and 
should thus preserve Th1 responses in our vaccination model. As Th1 cell death occurs at 
the second antigen encounter, we sought to determine whether STAT6 inhibition at the 
time of infection would preserve Th1 responses. The same vaccination and infection 
strategy was utilized as in Figure 3.4 except a group of mice received daily IP injections 
of 10mg/kg STAT6 inhibitor (AS1517499) for 6 days total, beginning 3 days prior to 
infection and continuing 2 days after infection (Figure 3.5A). The results demonstrate 
that STAT6 inhibition does indeed preserve Th1 responses as indicated by the increased 
frequency and total number of GP61
Tet+
 CD4 T cells as compared to mice that did not 
receive the inhibitor (Figure 3.5B, upper panels). The increase in antigen-specific CD4 T 
cells also corresponded to an increase in their function as there were significantly 
increased frequencies of both IFNγ and TNFα producing cells, further indicating the 
restoration of Th1 responses when STAT6 signaling is nullified (Figure 3.5B, lower 
panels). Furthermore, the increase in CD4 responses also corresponded to an increase in 
GP33
Tet+
 CD8 T cells in frequency and number upon STAT6 inhibition (Figure 3.5C, 
upper panels) as well as an increase in TNFα+ CD8 T cells but not IFNγ+ CD8 T cells 
(Figure 3.5C, bottom panel). Again, this preliminary experiment includes just two mice 
and therefore no statistical analyses were performed. 
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Figure 3.5. Inhibition of STAT6 signaling at time of Clone 13 infection rescues 
protective vaccine responses in neonatal mice.  
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Neonatal IL-13Rα1+/+ (HR+/+) C57BL/6 mice were immunized IP with 10µg each of 
LCMV GP33-41 and GP61-80 peptides in IFA at 3 days of age. Eight weeks later, mice 
were infected IV with 2x10
6
 PFU LCMV Cl13. Some of the mice received IP STAT6 
inhibitor at 10mg/kg daily for 6 days beginning 3 days prior to infection and continuing 2 
days after infection (Inh) while other did not (Nil). 46 days after infection mice were 
sacrificed and splenic T cell responses were measured after ex vivo stimulation with 
GP33/61 peptides.  
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5. Discussion 
The transition of a newborn from a sterile intra-uterine environment to the microbe-rich 
world we live in marks a unique immunological milestone. At this moment, an infant 
encounters both microbial friends and foes which will shape the health of the newborn 
throughout infancy and, potentially, well into adulthood. During this neonatal period, the 
immune system is not yet fully functional. This functional defect manifests in poor 
inflammatory responses and impaired Th1 immunity while Th2-type responses are 
dominant. While such a bias is critical for fetal engraftment and maintenance of 
pregnancy
4, 5, 6
, it renders the newborn susceptible to microbial infection and precludes 
the efficacy of early life vaccination. Herein, we demonstrate that IL-4/IL-13 
heteroreceptor (HR) expression on neonatal Th1 cells contributes to poor vaccination that 
is common in early life. Genetic deletion of the HR, as well as interference with 
downstream signaling through STAT6 inhibition allow for restoration of adaptive 
immunity.  
 Initially, studies were performed using LCMV Arm as the infectious model to test 
whether early life vaccination was successful. Even though HR
-/- 
mice displayed 
significantly reduced viral titers in various organ there was no difference in the T cell 
responses to this acute virus. This makes sense in consideration of the findings by 
Matloubian, et al
209
 that demonstrate depletion of CD4 T cells does not affect the ability 
of CD8 T cells to completely clear an acute LCMV Arm infection. Since CD8 T cells are 
not known to express the HR, HR-deficiency had no effect on T cell responses. It is likely 
that HR
-/-
 mice display reduced viral titers due to the influence of the HR on other 
neonatal immune cells. The HR is expressed on most myeloid cells
185
 and we have 
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previously shown that neonatal basophils, which express the HR and produce significant 
IL-4, diminishes the function of early life dendritic cells
119
. While studies using DC-
ablated mice show that DCs are not required for clearance of LCMV Arm infection
210
, 
the abundant IL-4 in HR
+/+
 mice as compared to HR
-/-
 mice may explain the discrepancy. 
With abundant IL-4, as is the case in the neonatal system in general, but especially in the 
HR
+/+
 mice
119
, it is possible that the entire immune response may be modulated so that 
virus is not cleared as efficiently as when there is less IL-4 like in HR
-/-
 mice.  
 The findings that HR-deficiency allows enhanced neonatal vaccination are 
exciting and highlight potential new areas to explore. While it is not clinically feasible to 
block STAT6 signaling, as blockade of this pathway must occur at the secondary 
response, i.e. at the time of infection, and it is impossible to know when exposure to virus 
will occur, our findings do solidify prior evidence that HR signaling stifles neonatal 
immunity and extends our knowledge that this is operative in an early-life vaccination 
context. Avenues which preserve Th1 immunity will likely prove fruitful in the endeavor 
to boost neonatal vaccine efficacy.  
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